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Serum and Glucocorticoid-Regulated Kinase Signaling in Breast Cancer 
 
 
Abstract 
Oncogenic activating mutations in PIK3CA, the gene encoding the catalytic 
subunit of phosphoinositide 3-kinase (PI 3-K), are highly prevalent in breast cancer. The 
protein kinase Akt is considered to be the primary effector of PIK3CA, though the 
mechanisms by which PI 3-K mediates tumorigenic signals in an Akt-independent 
manner remain obscure. My studies show that the serum and glucocorticoid-regulated 
kinases (SGKs) can function as effectors of PI 3-kinase and transduce signals to 
phenotypes associated with malignancy.  We show that SGK3 is amplified in breast 
cancer and identify the mechanism by which SGK3 is activated downstream of PIK3CA, 
specifically through the catalytic activity of the phosphoinositide phosphatase INPP4B. 
Expression of INPP4B promotes SGK3 activation and in turn inhibits Akt 
phosphorylation.  In breast cancer cell lines with elevated levels of INPP4B, SGK3 is 
required for proliferation in 3D and also for invasive migration.  SGK3 phenotypes are in 
part mediated by phosphorylation of the substrate protein N-myc downstream regulated 
1 (NDRG)1, an established metastasis suppressor.  The phosphorylation of NDRG1 
leads to recruitment by F-box and WD repeat domain-containing 7 (FBW7), the 
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substrate recognition domain of the Skp, Cullin, F-box containing (SCF) complex.  
Binding of FBW7 to NDRG1 promotes its polyubiquitination and subsequent 
degradation by the 26S proteasome. By contrast, our studies also show that the related 
SGK1 isoform is polyubiquitinated by the functional E3 ubiquitin ligase Rictor-Cullin-1 
complex, leading to SGK1 degradation. Proteasomal degradation of SGK1 by Rictor-
Cullin-1 is the first identified mTORC2-independent function of the Rictor protein.  
Moreover, the deregulation of SGK1 ubiquitination highlights a mechanism of SGK1 
overexpression in breast cancers. 
Taken together, these findings highlight novel post-translational modifications of 
SGK isoforms converging on the theme of ubiquitination and degradation.  Alterations in 
ubiquitination status lead to the deregulation of cellular phenotypes such as proliferation 
and migration.  The data presented in this thesis also highlight a mechanism by which 
SGK isoforms transduce oncogenic PI3-kinase signaling in breast cancer.  The 
oncogenic potential of SGK signaling is further emphasized by the aberrant expression 
levels of SGK1 and SGK3 in breast cancers. 
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CHAPTER 1 
INTRODUCTION 
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1. MECHANISMS OF PI 3-KINASE ACTIVATION 
Phosphoinositide 3-Kinase (PI 3-K) is a lipid kinase family divided into 3 classes: 
class I, II, and III.  Class IA PI 3-Ks are heterodimeric enzymes composed of regulatory 
and catalytic subunits that are activated upon growth factor stimulation of Receptor 
Tyrosine Kinases (RTK) and G-Protein Coupled Receptors (GPCR).  The p85α (p85α, 
p50α, p55α), p85β, and p55γ regulatory subunits are encoded by three distinct genes 
PIK3R1, PIK3R2, and PIK3R3 and are collectively referred to as p85. The regulatory 
subunits are capable of binding the catalytic subunits p110α, p110β, and p110δ 
encoded by PIK3CA, PIK3CB, PIK3CD, respectively (Courtney et al., 2010; Hawkins et 
al., 2006).  p85 subunits contain Src Homology 2 (SH)2 and SH3 domains that bind 
phosphorylated tyrosine residues of RTKs or their adaptor proteins (Manning and 
Cantley, 2007). RTKs such as Insulin-like Growth Factor 1-Receptor (IGF1-R) and 
Platelet-Derived Growth Factor-Receptor (PDGF-R) harbor intrinsic tyrosine kinase 
activity and upon growth factor-induced dimerization of the receptor, the dimers 
transphosphorylate tyrosine residues in the cytoplasmic tail regions (Hawkins et al., 
2006).  The p85 regulatory subunits function to inhibit the activity of the p110 catalytic 
subunit until the SH2 domain of p85 binds phosphotyrosines on the RTK, within the 
common consensus sequence pYXXM (Y, tyrosine; X, any amino acid; M, methionine) 
(Hawkins et al., 2006; Okkenhaug, 2013).  The binding of p85 to RTKs elicits the 
release of intermolecular p110 inhibition, thus activating PI 3-K and downstream 
signaling (Courtney et al., 2010).  In vitro PI 3-K phosphorylates the 3’ position of the 
inositol ring of the phosphoinositides PI (phosphatidylinositol), PI(3)P 
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(phosphatidylinositol (3) phosphate) and PI(4,5)P2 (phosphatidylinositol (4,5) 
bisphosphate) (Toker, 2000).  However in cells, class I PI 3-K primarily phosphorylates 
the substrate PI(4,5)P2 to generate PI(3,4,5)P3 (Miller et al., 2011; Toker, 2000).  In 
turn, PI(3,4,5)P3 recruits downstream effector proteins that harbor lipid binding 
domains, thus transducing the PI 3-K signal to secondary signal relay pathways (Figure 
1-1).  In addition to RTK regulation, PI 3-K is localized by Ras binding to p110 effectively 
localizing PI 3-K to the plasma membrane (Courtney et al., 2010; Hawkins et al., 2006). 
p110β is unique as a Class 1A PI 3-K to be recruited and activated by GPCRs. In 
response to GPCR ligand stimulation, Class 1B PI 3-K also interconverts PI(3,4,5)P3 
from PI(4,5)P2.  Unlike Class IA enzymes, Class 1B PI 3-K consists of heterodimers of 
p110γ encoded by the PIK3CG gene and the regulatory subunits p87 or p101. Class 1B 
PI 3-K are predominantly expressed in immune cells and are known for roles in 
inflammatory diseases and immunity (Hawkins et al., 2006). Class IA PI 3-K is the class 
most prominently implicated in cancer etiology and progression by transducing growth 
factor responses as well mediating oncogenic signaling (Yuan and Cantley, 2008). 
Class II PI 3-kinases generate PI(3)P and PI(3,4)P2 from PI and PI(3)P and lack any 
known regulatory domains. PI 3-K-C2α, PI 3-K-C2β, and PI 3-K-C2δ are class II 
enzymes and possess a C2 domain (Hawkins et al., 2006; Okkenhaug, 2013).  Little is 
known about the functional roles of Class II PI 3-K, although they are known to be 
activated by insulin signaling and as such they modulate PI 3-K signaling in insulin-
responsive cells and tissues (Okkenhaug, 2013). 
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Figure 1-1: The phosphoinositide 3-kinase cascade 
The phosphoinositide 3-kinase (PI3-K) signaling cascade. PI3-K signaling impacts on 
cell growth, survival, and metabolism. Arrows represent activation, while bars reflect 
inhibition. (*) p110 alpha, beta, or delta.  Taken from (Courtney et al., 2010). 
 
	   5	  
Class III PI 3-kinases exclusively produce PI(3)P from PI, and are composed of a 
VPS34 catalytic domain and p150 regulatory domain (Backer, 2008).  The primary role 
of Class III PI 3-kinases and the lipid product PI(3)P is to modulate endosomal protein 
sorting and membrane trafficking (Backer, 2008; Okkenhaug, 2013).  
 
The Akt Kinase as a Transducer of PI 3-K Signaling 
A major effector of the PI 3-K signaling axis is the serine/threonine protein kinase 
Akt, also known as Protein Kinase B (PKB) (Luo et al., 2003). Under basal serum-
starved conditions Akt is a cytosolic enzyme. Upon activation of PI 3-K, Akt translocates 
to the plasma membrane by binding PI(3,4,5)P3 and PI(3,4)P2 through the amino-
terminal Pleckstrin Homology (PH) domain (Luo et al., 2003). As discussed above, 
PI(3,4,5)P3 is generated by Class I PI 3-K, whereas PI(3,4)P2 is synthesized by Class II 
PI 3-K. An alternate route for PI(3,4)P2 accumulation is dephosphorylation of 
PI(3,4,5)P3 by the SH2 domain-containing Inositol 5' Phosphatases (SHIP) 1 and 2,  
which are PI(3,4,5)P3 5’ inositol phosphatases (Choi et al., 2002; Elong Edimo et al., 
2013; Scheid et al., 2002). Subsequent to the lipid binding-induced conformational 
change, Akt is phosphorylated at two critical residues in the catalytic domain, Thr308 in 
the activation loop and Ser473 in the Hydrophobic Motif (HM) (Luo et al., 2003; Toker, 
2000).  Thr308 (in Akt1) is phosphorylated by the Phosphoinositide-Dependent Kinase -
1 (PDK-1), which is also recruited to PI(3,4,5)P3 and PI(3,4)P2 through its carboxyl-
terminal PH domain (Mora et al., 2004).  PDK-1 is a constitutively active protein kinase 
primarily due to autophosphorylation at the activation loop residue Ser241 (Mora et al., 
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2004).  The HM of Akt isoforms (Ser473 in Akt1) is phosphorylated by the mammalian 
Target Of Rapamycin Complex 2 (mTORC2), although a number of other kinases have 
been shown to replace the function of mTORC2 as the Ser473 kinases, including 
Protein Kinase C (PKC), Integrin-Linked Kinase (ILK) and Akt itself (Lu et al., 2006; 
Miller et al., 2011; Xia et al., 2004).  Regardless of the mechanism, phosphorylation of 
Akt by mTORC2 promotes a conformational change allowing PDK-1 access to the Akt 
activation loop (Figure 1-2) (Sarbassov et al., 2005).  Both Ser473 and Thr308 
phosphorylation are required for maximal Akt catalytic activity (Courtney et al., 2010; 
Woodgett, 2005). Upon activation, Akt is locked in the catalytically-active confirmation 
and loses the PI(3,4,5)P3 or PI(3,4)P2 binding requirement (Mora et al., 2004; 
Sarbassov et al., 2005). Newly activated Akt then translocates to numerous intracellular 
compartments to interact and phosphorylate an array of substrates critical for 
metabolism, growth, and survival(Luo et al., 2003). Importantly, the levels PI(3,4,5)P3 in 
all cells and tissues are negatively regulated by the tumor suppressor Phosphatase and 
Tensin homolog deleted on chromosome ten (PTEN). PTEN converts PI(3,4,5)P3 back 
to PI(4,5)P2 effectively terminating PI 3-K signaling (Figure 1-3) (Li et al., 1997; 
Maehama and Dixon, 1998). As discussed below, inactivation of PTEN is a frequent 
event in cancer and leads to constitutive PI(3,4,5)P3 levels and hyperactivation of Akt 
(Engelman et al., 2006). Alternately, a distinct tumor suppressor Inositol Polyphosphate 
4-Phosphatase type II (INPP4B) also negatively regulates Akt by dephosphorylating 
PI(3,4)P2 at the 4’ position effectively generating PI(3)P (Fedele et al., 2010; Gewinner 
et al., 2009).  
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Figure 1-2: Activation mechanism of Akt 
 
The generation of PI(3,4,5)P3 from PI(4,5)P2 by PI 3-K recruits Akt to the membrane.  
Here, it is phosphorylated by PDK-1 and mTORC2 required for maximal Akt activation.  
Adapted from (Pearce et al., 2010). 
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Figure 1-3: PI 3-K catalyzed inositol phospholipid pathways 
The main metabolic pathways that interconvert inositol phospholipids in eukaryotic cells 
are shown. Class I phosphoinositide 3-kinases (PI 3-Ks) are activated by cell surface 
receptors to make phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) and, indirectly, 
PtdIns(3,4)P2; these two lipids are intracellular signals that carry important information 
through the receptor signaling network. Class III and probably class II PI3Ks make 
PI(3)P and play a key part in regulatory networks controlling vesicular trafficking through 
the endosome–lysosome system. DAG, diacylglycerol; FAB1, PI(3)P 5-kinase; INPP5, 
inositol polyphosphate 5-phosphatase; MTM, myotubularin; PLC, phospholipase C; 
PTEN, phosphatase and tensin homologue; SHIP, SH2 domain-containing inositol 5′-
phosphatase.  Adapted from (Vanhaesebroeck et al., 2012). 
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Again, inactivation mutations or loss of heterozygosity (LOH) of INPP4B leads to 
increased accumulation of PI(3,4)P2 and constitutive Akt activation (Gewinner et al., 
2009). 
There are three Akt isoforms encoded by three distinct genes: Akt1/PKBα, 
Akt2/PKBβ and Akt3/PKBγ.  All three isoforms are basophilic-directed serine/threonine 
protein kinases that share a conserved consensus substrate phosphorylation motif,  
with Arginine at the -3 and -5 position and a preference for hydrophobic residues at +1, 
relative to the Ser/Thr phospho-acceptor residue (Murray et al., 2004; Tessier and 
Woodgett, 2006b).  Akt1, Akt2 and Akt3 are ubiquitously expressed in all tissues and 
organs in humans. Akt isoforms are members of the AGC (PKA, PKG, PKC) family of 
kinases and share certain common elements in their mechanisms of regulation, since 
most AGC kinases are phosphorylated at their activation loop residues by PDK-1 and at 
the HM motif by mTORC2. Although all three Akt isoforms are activated by identical 
mechanisms through lipid binding and PDK-1- and mTORC2-catalyzed phosphorylation, 
Akt1, Akt2 and Akt3 have multiple non-redundant roles in signaling and 
pathophysiology. One clear example of Akt isoform-specific signaling was first identified 
in breast cancer cells, whereby Akt1 and Akt2 possess opposing roles in the regulation 
of cell migration and invasion (Toker and Yoeli-Lerner, 2006).  Akt2 functions to promote 
invasive migration in part by the induction of β1integrin expression (Arboleda et al., 
2003). Conversely, Akt1 inhibits migration, invasion and even metastatic dissemination 
in vivo, in part through the degradation of Nuclear Factor of activated-T cells (NFAT), 
modulation of the Extracellular-Regulated Kinase (ERK) pathway, and inhibition of actin 
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bundling (Toker and Yoeli-Lerner, 2006; Yoeli-Lerner et al., 2005). Akt isoform signaling 
specificity is also mediated through inactivation of its catalytic activity by protein 
phosphatases.  Specifically, Akt signaling is terminated by the PH domain and Leucine-
rich Protein Phosphatases 1 and 2 (PHLPP)1/2 (Brognard and Newton, 2008; Brognard 
et al., 2007).  PHLPPs are a family of serine/threonine phosphatases that 
dephosphorylate Akt isoforms at Ser473.  Interestingly, PHLPP1 has been shown to 
dephosphorylate Akt2 and Akt3 at S474 and Ser472, respectively, whereas PHLPP2 
dephosphorylates Akt1 and Akt3 at their corresponding HM residue (Brognard and 
Newton, 2008; Brognard et al., 2007). 
Akt transduces the PI 3-K signal in both normal physiological conditions as well as 
pathophysiological settings by phosphorylating a wide range of substrates that control 
virtually all aspects of cell biology, including but not limited to cell motility, growth, 
proliferation and survival (Luo et al., 2003). The first identified function for Akt in both 
cancer cells and neuronal tissues is induction of cell survival mechanisms under 
conditions of stress, mediated by the phosphorylation of substrates involved in 
apoptosis such as BCL-2 Agonist of cell Death (BAD) (Datta et al., 1997), that promotes 
cell survival subsequent to Akt-mediated phosphorylation.  Cell cycle progression is also 
mediated by Akt signaling, and phosphorylation of the F-box protein S phase Kinase-
associated Protein 2 (SKP2) by Akt promotes the formation of the Skp, Cullin, F-box 
containing (SCF) complex, an E3 ligase leading to p27 degradation, thus promoting cell 
cycle progression (Gao et al., 2009).  Forkhead box O 3A (FOXO3A) phosphorylation by 
Akt promotes FOXO3A nuclear export and cytoplasmic retention leading to inhibition of 
	   11	  
transcription of genes that control cell cycle arrest and apoptosis, effectively promoting 
survival (Singh et al., 2010).  Akt is directly involved in the activation of the  
mammalian Target of Rapamycin Complex 1 (mTORC1), and does so by 
phosphorylating the Tuberous Sclerosis Complex (TSC)1/TSC2, leading to TSC 
inhibition and subsequent downstream activation of mTORC1 (Luo et al., 2003).  The 
activation of mTORC1 in turn integrates critical cellular growth signals including 
feedback inactivation of the PI 3-K and Akt pathway.  mTORC1 activation is further 
facilitated through Akt-mediated phosphorylation of Proline-Rich Akt Substrate of 40 
kDa (PRAS40) leading to binding of 14-3-3 and release of mTORC1 inhibition (Vander 
Haar et al., 2007). 
Although many of the over 200 substrates of Akt are likely to be phosphorylated by 
all three Akt isoforms, a number of studies have uncovered a number of Akt isoform-
specific substrates that explain, in part, the non-redundant function of Akt’s in 
phenotypes associated with malignancy. For example, Akt1 exclusively phosphorylates 
palladin, an actin bundling protein, and this event mediates the ability of Akt1 to function 
as a suppressor of breast cancer cell invasive migration. Similarly, SKP2 has been 
shown to be an exclusive Akt1 substrate. Akt2 specific substrates include AS160 in the 
regulation of glucose transport and Myosin5a in the regulation of glut4 vesicular 
translocation (Chin and Toker, 2011; Toker, 2012). To date, no Akt3-specific substrates 
have been identified, although these are likely to exist.  
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Alternate PI 3-K Pathway Effectors 
Although Akt is generally considered to be the primary effector of PI 3-Kinase, it is by 
no means the exclusive transducer of PI(3,4)P2 and PI(3,4,5)P3.  Since PI 3-K signal 
relay is initiated by PI(3,4)P2 and PI(3,4,5)P3 accumulation at the plasma membrane, a 
rate limiting event in PI 3-K signal relay is the recruitment of effectors to the plasma 
membrane.  Other than Akt and PDK-1, other PH domain-containing proteins have been 
identified and are recruited by binding to PI(3,4,5)P3 and PI(3,4)P2, although it is worth 
noting that all PH domains bind phosphoinositides selectively or with high affinity.  Of 
the ones that do, the Tec family of non-receptor protein tyrosine kinases, including Tec, 
Bruton’s Tyrosine Kinase (BTK), Interleukin-2-Inducible T-cell Kinase (ITK), and Bone 
Marrow kinase on chromosome X (BMX), bind to PI(3,4,5)P3 through their PH domains 
(Vargas et al., 2013).   Moreover, the PH domain of BTK is critical for in vitro kinase 
activity and substrate recognition and binding (Saito et al., 2001).  Another class of 
effectors are Guanine Nucleotide Exchange Factors (GEFs) for small Guanosine 5’-
Triphosphate (GTP)ases, whereby recruitment positions the GEF in proximity with its 
GTPase in addition to relieving PH domain inhibition of the catalytic region (Cherfils and 
Zeghouf, 2013; Stalder and Antonny, 2013). The GEFs of the small GTPase ADP 
Ribosylation Factor (ARF) and also Ras-related C3 botulinum toxin substrate (RAC) 
control ARF and RAC activity thus regulating cytoskeletal changes leading to 
lamellipodia formation in a manner that is PI 3-K-dependent (DiNitto et al., 2007; Stalder 
and Antonny, 2013).  Regulation of cytoskeletal dynamics by PI 3-K is also mediated by 
Tandem PH-domain containing Proteins 1/2 (TAPP)1/2, that contain both amino-
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terminal and carboxyl-terminal PH domains (Hogan et al., 2004).  In addition, General 
Receptor for 3-Phosphoinositides 1 (GRP1) is the GEF that modulates the activation of 
ARF6, whereby the PH domain is critical for GRP1 localization in the activation of ARF6, 
leading to Glut4 vesicle formation and metabolic homeostasis (Langille et al., 1999).   
Therefore, effectors of PI(3,4)P2 and PI(3,4,5)P3 other than Akt and PDK-1 modulate a 
large network of downstream secondary signal relay pathways that in turn control 
numerous cellular processes from metabolism to growth and cell motility. However, it is 
generally considered in the field that many other effectors of PI 3-K exist in cells that 
respond to PI(3,4)P2 and PI(3,4,5)P3, and ascribing phenotypes linked to PI 3-K in 
pathophysiology to specific effectors remains a challenge in the field.  
 
Oncogenic PI 3-K Pathway Mutations 
The functional importance of PI 3-K signaling in cancer is most obviously evident by 
the number of oncogenic mutations that exist in genes that encode proteins that both 
regulate PI 3-K, PI 3-K itself and effectors of PI 3-K.  PIK3CA is one of the most 
frequently mutated genes in breast cancer, with a mutation rate approximating 35% 
especially in hormone receptor positive breast tumors (Yuan and Cantley, 2008).  The 
majority of PIK3CA mutations exist in two hotspot regions of exon 9 and exon 20, within 
the helical and catalytic domains, respectively.  E542K, E545K, and H1047R mutations 
account for 80% of the PIK3CA mutations in breast cancer (Courtney et al., 2010; Miller 
et al., 2011).  These hotspot mutations are gain-of-function mutations that cause 
hyperactivation of p110α and downstream signaling by alleviating the inhibitory effects 
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of the SH2 domain of p85 under basal conditions.  PIK3CA mutations are also frequent 
in other solid tumors, including endometrial carcinoma and colon carcinoma. Somatic 
mutations in Akt genes have also been identified, albeit at lower frequency that PIK3CA 
mutations. The Akt1 E17K mutation is oncogenic and promotes constitutive Akt 
signaling in the absence of growth factors (Brugge et al., 2007). This mutation at E17 
within the PH domain of Akt causing hyperactivation of the kinase, likely due to reduced 
specificity PI (3,4,5)P3 and PI(3.4)P2 such that the enzyme can interact with the more 
abundant PI(4,5)P2. In breast cancer Akt1 E17K mutations have been identified at a 
frequency of 1.5-8%, depending on the study (Yuan and Cantley, 2008). A recent whole 
cancer genome sequencing study identified an Akt2 E17K mutation in one patient, and 
an Akt3 E17K mutation has been described in the metastatic setting of a breast cancer 
patient.  Interestingly, E17K mutations in Akt3 appear to occur with high frequency in 
melanoma (Davies et al., 2008). 
PTEN inactivation is the most common PI 3-K pathway mutation across combined 
cancer subsets, with an inactivation frequency in breast cancer of approximately 30% 
(Miller et al., 2011).  PTEN inactivation leads to hyperactivation of the PI 3-K pathway 
since the major mechanism of PI 3-K signal termination, PI(3,4,5)P3 dephosphorylation, 
is absent. However, even in the context of PTEN inactivation, PI(3,4,5)P3 must still be 
synthesized, and generally PIK3CA mutations and PTEN inactivation are not 
synonymous, at least in breast cancer. Instead, studies have shown that the primary 
route of PI(3,4,5)P3 synthesis in PTEN-deficient tumors is the PIK3CB isoforms (Wee et 
al., 2008). Ultimately, elevated levels of PI(3,4,5)P3 lead to constitutive downstream Akt 
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activation and substrate phosphorylation.  PTEN inactivation occurs via distinct 
epigenetic and somatic mechanisms including missense mutations, truncation, 
homozygous and heterozygous deletion, and epigenetic silencing.  Germline PTEN 
mutations lead to hamartoma syndromes of Cowden disease, Bannayan-Riley-
Ruvalcaba syndrome and (Hobert and Eng, 2009; Song et al., 2012). 
Since p21 Ras binding to p110α controls PI 3-K activation, Ras mutations contribute 
to pathway activation. Ras mutation across all cancer occur prominently at a frequency 
of approximately 30% (Adjei, 2001).  In breast cancer, Ras mutations are relatively 
infrequent but nonetheless significant with about 5% hyperactivation across all 
molecular subtypes (Miller et al., 2011). PI 3-K is critical for tumor initiation in Ras-
mutant tumors, however, established tumors show reduced dependence on PI 3-K.  
Pan-PI 3-K inhibitors alone may not be sufficient to abrogate late stage Ras-mediated 
tumorigenesis, but may underscore a potential preventative opportunity. 
Since Class 1 PI 3-Ks are activated downstream of RTKs, amplification of these 
receptors also leads to PI 3-K pathway hyperactivation in solid tumors. The Human 
Epidermal growth factor Receptor 2 (HER2/ ERBB2) is a member of the ErbB family of 
receptors and overexpression or amplification of HER2 is detected in approximately 
20% of all breast cancers (Yuan and Cantley, 2008). HER2 amplification leads to 
hyperactivation of not only PI 3-K but also PKC, ERK, Phospholipase C γ (PLCγ) and 
Signal Transducer and Activator of Transcription (STAT) pathways (Masuda et al., 
2012).  RTK amplification therefore leads to widespread deregulation and uncontrolled 
cell growth, making them a logical focus for therapeutic intervention.  HER2 is the target 
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for monoclonal antibody drugs such as Herceptin and Pertuzumab (Rexer and Arteaga, 
2013). 
 
The Inositol Polyphosphate Phosphatase INPP4B 
The importance of INPP4B in PI 3-K signaling was recently appreciated since 
inactivation of this putative tumor suppressor leads to elevated PI(3,4)P2 levels and 
consequent Akt hyperactivation, leading to increased cell proliferation and tumor 
initiation (Gewinner et al., 2009). The same studies also highlighted the fact that 
INPP4B is lost by genetic inactivation in basal-like/triple negative breast cancer (Fedele 
et al., 2010; Gewinner et al., 2009).  Breast cancer is subdivided into molecular 
subtypes with distinct profiles: triple-negative breast cancer (TNBC) or basal-like, HER2 
positive, Luminal A and Luminal B.  TNBC lack estrogen receptor (ER), progesterone 
receptor (PR), and HER2 (Patani et al., 2013). Basal-like breast cancers are further 
distinguished from triple negative subtype by immunohistochemical or gene expression 
analysis establishing basal biomarkers such as Epidermal Growth Factor Receptor 
(EGFR) and/or basal cytokeratins (CK5/6, CK14, CK17) (Patani et al., 2013).  Basal-like 
breast cancers also typically display a high mitotic index and histological grade, and are 
associated with more aggressive tumors.  HER2+ve breast cancers overexpress HER2, 
but not ER or PR.  Luminal subtype A breast cancers express ER and/or PR but not 
HER2 and have low Ki67, while Luminal B cancers express ER and/or PR and maintain 
high Ki67 (Patani et al., 2013). TNBC accounts for 15% of all breast cancer and are 
associated with poor prognosis.  55% of TNBC and 88% of basal-like carcinomas 
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display LOH of INPP4B (Fedele et al., 2010; Gewinner et al., 2009).  These findings 
argue that LOH of INPP4B is restricted to ER-ve tumors.  Furthermore, INPP4B loss is 
seen in 49% of PTEN-null tumors (Fedele et al., 2010).  Therefore, the correlation of 
INPP4B LOH combined with PTEN inactivation status implies that the concurrent loss of 
both phosphatases leads to hyperactivation of Akt in aggressive basal-like or TNBC, 
such that these tumors may particularly benefit PI 3-K-directed therapies. 
The tumor suppressor activity of INPP4B has been proposed to be due to its 
ability to dephosphorylate PI(3,4)P2 into PI(3)P, such that INPP4B LOH causes 
constitutive elevated levels of PI(3,4)P2 (Gewinner et al., 2009). Although two isoforms 
exist, Inositol Polyphosphate-4-Phosphatase type I (INPP4A) and INPP4B.  INPP4A is 
exclusively localized to neuronal tissues with no evidence of functional expression in 
cancer (Fedele et al., 2010). By contrast, INPP4B is defined as a tumor suppressor in 
breast, ovarian, prostate carcinomas and melanomas (Agoulnik et al., 2011).  INPP4B 
inactivation correlates with poor prognosis for long-term survival and highly metastatic 
tumor potential.  Interestingly, additional associations for INPP4B are documented in 
breast cancer, whereby 60% of cancers with BRCA1 germline mutations also have 
INPP4B LOH (Gewinner et al., 2009).  One study has shown that INPP4B knockdown 
with shRNA in breast cancer cells in vitro induces anchorage-independent cell growth 
(Fedele et al., 2010). Moreover, INPP4B overexpression in xenograft models inhibits the 
growth of BRCA1 mutant cells (Gewinner et al., 2009). 
Since INPP4B is lost by LOH with high frequency TNBC/basal like cancers, 
INPP4B expression has been proposed as a biomarker for Luminal A and Luminal B 
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subtypes. Specifically, a statistically significant expression of INPP4B in ER+ve has 
been described (Fedele et al., 2010).  Moreover, ER has been demonstrated to mediate 
the transcriptional induction of INPP4B (Fedele et al., 2010). Importantly, PIK3CA 
oncogenic mutations are mutually exclusive with INPP4B LOH, corroborating previous 
studies identifying 47% of ER+ve breast cancer tumors as PIK3CA mutant (Miller et al., 
2011).  INPP4B expression correlates with 75% of breast cancers that express ER 
and/or PR (Miller et al., 2011). 
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2. SERUM AND GLUCOCORTICOID-REGULATED KINASES 
Serum and Glucocorticoid-Regulated Kinase 1 (SGK1) was initially identified in a rat 
mammary tumor cell line as a glucocorticoid-induced gene (Tessier and Woodgett, 
2006b). SGKs are also in the AGC kinase family and comprise three isoforms each 
encoded by distinct genes: SGK1, Serum and Glucocorticoid-Regulated Kinase 2 
(SGK2) and Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) (Figure 1-4). SGK2 
and SGK3 were cloned and characterized due to high sequence similarity to SGK1.  
SGK1 and SGK3 isoforms are ubiquitously expressed, unlike SGK2, which is restricted 
to the liver, kidney, pancreas, and brain (Tessier and Woodgett, 2006b). SGK isoforms 
share a combined amino acid sequence identity of ~80% within the catalytic domains 
and ~50% within the carboxyl-terminal region.  SGK isoforms share an overall ~50% 
homology with the catalytic domains of Akt isoforms.  Structurally, three SGK isoforms 
diverge from one another at the amino-terminus. Specifically, the amino-terminus of 
SGK1 localizes it to the endoplasmic reticulum for subsequent degradation.  SGK2 on 
the other hand has a blunted amino-terminus with no known functions.  SGK3 has a 
Phox Homology (PX) domain that binds exclusively to PI(3)P (Tessier and Woodgett, 
2006a). SGK isoforms share the same substrate consensus phosphorylation motif as 
Akt, RXRXXS/T (Murray et al., 2004).  The only known distinction between the Akt and 
SGK consensus motifs is the +1 hydrophobic residue that is exclusive to Akt. To date, 
there is only one SGK substrate that is exclusive to the SGK family and is not targeted 
by Akt isoforms, N-myc Down-Regulated Gene (NDRG)1 (Tessier and Woodgett, 
2006b).  NDRG1 was originally identified as an SGK substrate using the KESTREL  
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Figure 1-4:  Serum and Glucocorticoid-regulated Kinase Isoforms 
 
SGK family isoforms share ~80% sequence homology in their catalytic domains and 
~50% sequence homology in their C-terminal region (Tessier and Woodgett, 2006b).  
They diverge in their N-terminal regions where SGK3 possesses a PX domain and 
SGK1 has 6 N-terminal Lysines (K) that target it for polyubiquitination and degradation 
by the 26S proteasome. SGK isoforms have two phosphorylation sites required for 
maximal activation: PDK-1 regulated catalytic domain site (SGK1, T256; SGK2, T193; 
SGK3, T320) and Hydrophobic motif site regulated by MTORC2, only formally 
demonstrated (SGK1, S422). 
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technology by the Cohen laboratory (Murray et al., 2004).  SGK isoforms also 
phosphorylate known Akt substrates such as FOXO3A, Glycogen Synthase Kinase β 
(GSK-3β), Raf, Neural precursor cell Expressed Developmentally Down-regulated 
protein 4-2 (NEDD4-2), and TSC2, highlighting redundancy in Akt and SGK downstream 
signaling mechanisms (Tessier and Woodgett, 2006b).  SGK knockout mice have 
yielded little information regarding physiological functions, although SGK1 knockout 
mice have sodium balance intolerances, and SGK3-null mice have defective hair follicle 
development (Lang et al., 2006; McDonald, 2008). Double knockouts have not yet been 
made and SGK2 null mice have also not been generated. 
Interestingly, SGK1 is the only SGK isoform induced by serum and/or 
glucocorticoids, such that the name ‘SGK’ is somewhat of a misnomer. A variety of 
other mechanisms lead to transcriptional induction of SGK1, including p53, 
Transforming Growth Factor β (TGFβ), Fibroblast-derived Growth Factor (FGF), 
Platelet-derived Growth Factor (PDGF), Follicle Stimulated Hormone (FSH), 
hyperosmotic stress, hypoxia, heat shock, UV irradiation and DNA damage (Tessier and 
Woodgett, 2006b). SGK1 expression is very transient and this underlies its mechanism 
of regulation. SGK1 is poly-ubiquitinated by NEDD4-2 and Carboxyl terminus of HSC70-
Interacting Protein (CHIP) E3 ligases, leading to degradation by the 26S proteasome 
(Brickley et al., 2002; Zhou and Snyder, 2005).  The degradation of SGK1 is controlled 
through the amino-terminus in which amino acids 18-24 direct SGK1 to the endoplasmic 
reticulum following poly-ubiquitinatination of six lysine residues within this domain. 
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In breast cancer, SGK1 expression correlates significantly with pAkt levels, however 
there is no correlation with tumor grade or ER status.  Studies have revealed that 40% 
of tumors overexpress SGK1 and concurrently elevated pAkt1 at S473 (Sahoo et al., 
2005).  Immunohistochemical analysis reveals that 48% of breast tumors overexpress 
SGK1 (Sahoo et al., 2005). Other studies have documented approximately 75% SGK1 
overexpression in breast cancer using tissue microarrays (Zhang et al., 2005).  
However, no studies have to date examined SGK1 activity in human tumors, primarily 
due to the lack of available tools to accurately determine kinase SGK activity.  However, 
a recent study by the Alessi laboratory identified SGK1 as an alternate pathway for 
breast cancers treated with Akt inhibitors (Sommer et al., 2013).  In this study a 
significant correlation is detected in cells that overexpress SGK1 and are also resistant 
to Akt inhibitors.  Additionally, these cell lines reveal high phosphorylation levels of 
NDRG1, a surrogate for high SGK activity (Sommer et al., 2013).  Proliferation is also 
significantly reduced in Akt inhibitor-resistant cells upon SGK1 knockdown, highlighting 
a novel role for SGK1 as a therapeutic target in breast cancer.  
 
Serum and Glucocorticoid-regulated Kinase Activation Mechanisms 
SGK isoforms share the same upstream kinases with Akt, PDK-1 and mTORC2.  As 
with Akt, both PDK-1 and mTORC2 phosphorylation are required to maximally activate 
SGK (Garcia-Martinez and Alessi, 2008; Kobayashi et al., 1999).  mTORC2 
phosphorylates the carboxyl-terminal HM of SGK1(Ser422) (Garcia-Martinez and Alessi, 
2008).  SGK2 and SGK3 are also likely mTORC2 substrates for the HM at Ser356 and 
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Ser486, respectively, although this has not formally been proven.  PDK-1 has been 
shown to phosphorylate the activation-loop of all SGKs (SGK1, Thr256; SGK2, Thr193; 
SGK3, Thr320) (Kobayashi et al., 1999).    However, there are some clear distinctions 
from Akt in the mechanism of regulation of SGK isoforms. For example, the PI 3-K-
dependence for SGK1 activation lies with the PDK-1 phosphorylation of the activation-
loop phosphorylation.  In this context, the With No lysine (K) 1 (WNK1) kinase is 
required for efficient PDK-1 docking and phosphorylation of SGK1 (Xu et al., 2005).  
WNK1 Thr58 phosphorylation is required for the correct confirmation of WNK1 to serve 
as scaffold, whereas its kinase domain is dispensable for SGK1 activation.   
Interestingly, Akt and SGK both phosphorylate WNK1 at Thr58 indicative of a possible 
feedback loop to promote SGK1 activity (Xu et al., 2005).  Although the precise 
mechanism by which PI 3-K contributes to SGK2 and SGK3 activation has yet to be 
defined, PI 3-K inhibitors to block SGK2 and SGK3 activity in cell-based assays 
(Kobayashi et al., 1999). In the case of SGK3, studies have shown that a functional PX 
domain and PI 3-K are necessary critical for maximal SGK3 phosphorylation at Thr320 
and Ser486, as well as SGK3 catalytic activity (Tessier and Woodgett, 2006a).  To this 
end, a point mutation (Arg90Ala) in the SGK3 PX domain which abolishes PI(3)P 
binding completely blocks SGK3 phosphorylation, indicating that both PI(3)P binding 
and PI 3-K signaling converge to activate this SGK isoform (Tessier and Woodgett, 
2006a). 
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Serum and Glucocorticoid-regulated Kinase 3 Regulation 
A recent study from the Garraway laboratory demonstrated that SGK3 can function 
to mediate Akt-independent signaling and cell proliferation in cells harboring oncogenic 
PIK3CA mutations (Vasudevan et al., 2009). This is relevant since studies have shown 
that a significant proportion of breast cancers are resistant to Akt inhibitors even in the 
context of oncogenic PI 3-K signaling.  In the Garraway study, cell lines that display low 
levels of Akt phosphorylation have elevated SGK3 activity.  Furthermore, breast cancer 
cell lines that show little or no dependence on Akt for anchorage-independent growth 
instead require SGK3 activity for proliferation and survival (Vasudevan et al., 2009).  
However, since SGK3 does not harbor a functional PH domain capable of sensing 
PI(3,4,5)P3 and PI(3,4)P2, the question remains how PIK3CA can utilize SGK3 as a 
bona fide effector.  
As discussed above, the PX domain of SGK3 binds PI(3)P and studies have shown 
that this event localizes SGK3 primarily to endosomal membranes that are enriched for 
this lipid.  Vacuolar Protein Sorting 34 (VPS34), the only Class III PI 3-Kinase, is thought 
to be largely if not exclusively responsible for the generating the pool of PI(3)P at the 
endosome (Backer, 2008). Importantly, as with Akt, SGK3 activity loses the PX domain 
and PI(3)P dependence after phosphorylation of the HM (Tessier and Woodgett, 
2006a).  Additionally mutation of the PDK-1 Interacting Fragment (PIF) pocket of SGK3 
attenuates Thr320 phosphorylation by PDK-1 (Tessier and Woodgett, 2006a).  This 
indicates that PDK-1 requires the PIF pocket to dock within the HM of SGK3, as with 
other AGC family kinases such as S6K1/2.   Furthermore, PI 3-K inhibitors combined 
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with PDK-1 overexpression does not inhibit the SGK3 Thr320 phosphorylation, 
suggesting that SGK1, SGK3 is not PI 3-K-dependent due to stabilization by PDK-1 
docking.  Instead, it is more likely that SGK3 depends upon PI 3-K for HM 
phosphorylation mediated by mTORC2, or for its localization and substrate interactions. 
Although the SGK3 gene is not regulated by glucocorticoids, it is transcriptionally 
upregulated by ER (Wang et al., 2011a). SGK3 protein levels correlate with ER status in 
both breast cancer cell lines and tumor samples, and SGK3 has been shown to induce 
estrogen-mediated survival of breast cancer cells (Wang et al., 2011a; Xu et al., 2012).  
The transcriptional induction by ER is of particular interest in Luminal subtype A and 
Luminal subtype B breast cancers, since approximately 75% breast cancers are ER+ve 
and thus likely also display elevated SGK3.  
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3.  N-MYC DOWN-REGULATED GENE 1 
N-myc down-regulated gene (NDRG) represents a family of four members encoded 
by distinct genes that share ~50% sequence homology: NDRG1, NDRG2, NDRG3 and 
NDRG4 (Figure 1-5).  The NDRG family is categorized within a subgroup of α/β 
hydrolase enzymes, although NDRG isoforms lack any hydrolytic catalytic activity 
(Melotte et al., 2010).  NDRG isoforms contain an NDR domain and a non-functional α/β 
hydrolase fold. No enzymatic activity of any kind has been ascribed to NDRG isoforms.  
NDRG1 is ubiquitously expressed in all human tissues, although elevated levels are 
detected in epithelial tissues (Sun et al., 2013a).  NDRG2 is primarily expressed in the 
brain, heart, spinal cord, and skeletal muscle. NDRG2 and NDRG4 isoforms display 
multiple splice variants and expressed exclusively in the brain and heart.   Interestingly, 
NDRG3 is expressed in all tissues except brain and heart (Melotte et al., 2010).   
NDRG1 is the only isoform that contains a carboxyl-terminal tandem 3X decapeptide 
repeat (Melotte et al., 2010).  Within each decapeptide are three SGK phosphorylation 
sites (Thr346, Thr356, Thr366) that are not phosphorylated by Akt.  Each SGK site 
primes NDRG1 for phosphorylation by GSK3β at the -4 residue (Ser342, Ser352 and 
Ser362) (Murray et al., 2004).  Therefore, in order to phosphorylate NDRG1, GSK3β 
requires prior NDRG1 phosphorylation by SGK3.   The overall consequence of these 
phosphorylation events at the cellular level remains to be determined.  The GSK3β and 
SGK3 sites in NDRG1 are conserved across species and to Danio rerio. (Figure 1-6)  
Although NDRG1 is primarily cytoplasmic, some studies show that NDRG1 can be 
recruited to the plasma membrane, endosomes, mitochondrial membranes, and the  
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Figure 1-5: NDRG family isoforms 
NDRG isoforms 1-4 share common N-myc Down-Regulated (NDR) domains and non-
functional a/b hydrolase domains.  NDRG1 has a unique C-terminal 3X decapeptide 
repeat. 
NDRG1!
NDRG2!
NDRG3!
NDRG4!
NDR- domain! α/β hydrolase!
fold!
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Figure 1-6: NDRG1 3X decapeptide conservation 
 
NDRG1 3X decapeptide repeat is conserved from Homo sapiens to Danio rerio.  The 
decapeptide repeat is highlighted in grey and SGK substrate phosphorylation motif is 
written in red. 
 
 
 
 
Homo sapiens  321: trlmrsrtas gssvtsldgt rsrshtsegt rsrshtsegt  rsrshtsega 
Mus musculus  321: trlmrsrtas gssvtslegt rsrshtsegp rsrshtsegs  rsrshtseda 
Xenopus tropicalus  321: trlmrsrtgs aassssqdgn rsrshtnegs rsrshtgdgn  rsrahtgdgn 
Danio rerio         307: trlvrsrtas gssitsfdgn rsrshtnegn rsrshtneg-  rarahtsenq 
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nucleus (Sun et al., 2013a).  Although NDRG1 has no established nuclear localization 
sequence, it is known to associate with transport proteins such as Heat-Shock Cognate 
Protein 70 (HSC70) (Sun et al., 2013a). Moreover, membrane-associated NDRG1 is 
localized to adherens junctions, indicating a possible interaction with the cytoskeletal 
components that cooperate with these junctions. 
In addition to post-translational modification, NDRG1 is regulated at the 
transcriptional level. NDRG isoforms possess a 5’ CpG island within their promoter 
regions suggesting their expression is regulated by DNA methylation (Melotte et al., 
2010).  Oncogenes such as N-neuroblastoma-derived myelocytomatosis (N-myc) and 
Cellular V-myc myelocytomatosis viral oncogene homolog (C-myc) down-regulate 
NDRG expression, hence their gene nomenclature.  In addition, NDRG1 is regulated by 
a wide range of other cellular factors and extracellular stimuli and agents, including 
Hypoxia-Inducible Factor 1 (HIF1), p53, nickel, cobalt, vitamin A, vitamin D, steroids, 
heavy metal chelators, and oxidative stress (Melotte et al., 2010).  
 
NDRG1 Regulation During the Epithelial-Mesenchymal Transition 
NDRG1 has been documented to function as a metastasis suppressor (Sun et al., 
2013a).  In this context, initial studies identified a role for NDRG1 in the vesicular 
recycling of E-cadherin (Kachhap et al., 2007). NDRG1 interacts with membrane-bound 
Rab4a GTPase at the recycling endosomes of the Trans Golgi network to shuttle E-
cadherin to the plasma membrane, thereby stabilizing the adherens junction complex 
(Kachhap et al., 2007).  In turn, stabilization of the actin cytoskeleton leads to decreased 
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cell motility and reduced invasive migration.  The elevated levels of E-cadherin at 
adherens junctions also reduce the rate of Epithelial- Mesenchymal Transition (EMT), a 
critical step in the progression to metastasis (Figure 1-7). 
NDRG1 has been shown to modulate EMT by promoting the down-regulation of the 
TGFβ signaling pathway (Chen et al., 2012).  For example, NDRG1 suppresses the 
expression of TGFβ targets Snail, Slug and Smad leading to suppression of EMT and 
metastasis.  NDRG1 has also been implicated in inhibiting metastasis through 
Wingless-related integration site (Wnt) signaling, by binding the Low-density Lipoprotein 
Receptor-related Protein 6 (LRP6), a coreceptor for the canonical Wnt pathway (Liu et 
al., 2012).  NDRG1 binding blocks Wnt downstream signaling, thus preventing 
accumulation and nuclear translocation of β-catenin.  The nuclear entry of β-catenin 
upregulates the activity of the T-Cell Factor (TCF) family of transcription factors.  TCF 
family members induce the transcription of oncogenic proteins such as Myc, Cyclin D, 
Cluster of Differentiation 44 (CD44), and Matrix Metalloproteinase 7 (MMP7) that 
promote cell cycle progression, tumor growth, and cancer metastasis (Liu et al., 2012). 
 
Clinical Significance of NDRG1 Expression and Function 
NDRG1 protein and mRNA levels have been found to be decreased in breast, 
prostate, colon, and glioma cancers relative to normal tissue (Sun et al., 2013a). 
Therefore, there is increasing evidence that supports NDRG1 as a tumor suppressor 
and/or a metastasis suppressor.  In breast tumors, an inverse correlation in NDRG1 
expression and ERα status has been documented (Sun et al., 2013a).  Similarly, ectopic  
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Figure 1-7: EMT 
An EMT involves a functional transition of polarized epithelial cells into mobile and ECM 
component–secreting mesenchymal cells. The epithelial and mesenchymal cell markers 
commonly used by EMT researchers are listed. Colocalization of these two sets of 
distinct markers defines an intermediate phenotype of EMT, indicating cells that have 
passed only partly through an EMT. Detection of cells expressing both sets of markers 
makes it impossible to identify all mesenchymal cells that originate from the epithelia via 
EMT, as many mesenchymal cells likely shed all epithelial markers once a transition is 
completed. For this reason, most studies in mice use irreversible epithelial cell–lineage 
tagging to address the full range of EMT-induced changes. ZO-1, zona occludens 1; 
MUC1, mucin 1, cell surface associated; miR200, microRNA 200; SIP1, survival of 
motor neuron protein interacting protein 1; FOXC2, forkhead box C2.  Taken from 
(Kalluri and Weinberg, 2009). 
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expression of ERα in ERα negative cells induces down-regulation of NDRG1 and 
suppression of NDRG1 leads to increased invasive migration that can be rescued by 
reintroduction of NDRG1. 
In a study of 240 colorectal cancers, NDRG1 levels inversely correlated with tumor 
grade, metastatic lesions, and differentiation status (Mao et al., 2013).  Importantly, 
NDRG1 expression is a positive prognostic marker for long-term survival at 5+ years.  
Similarly in neuroblastoma patients, decreased NDRG1 mRNA is linked to poor 
prognosis and metastastatic dissemination (Matsushita et al., 2013).  Similarly, in 
hepatic cancers cells NDRG1 suppresses growth though cell cycle arrest, and loss of 
NDRG1 in ovarian carcinoma cells leads to enhanced invasive migration (Zhao et al., 
2011).  In pancreatic cancer NDRG1 is a positive prognostic marker for long-term 
patient survival, and loss of NDRG1 expression in pancreatic cancer is indicative of 
invasive tumors with high levels of angiogenesis and overall tumor growth.  In this 
model, rescued expression of NDRG1 leads to suppression of angiogenic phenotypes 
and reduced tumor growth via suppression of NFκB signaling (Hosoi et al., 2009).  
More recently, epigenetic regulation of NDRG1 through a previously undocumented 
microRNA pathway has been identified.  miR 182 promotes prostate cancer 
proliferation, growth, and invasion through the down-regulation of NDRG1 (Liu et al., 
2013).  The microRNA binds the 3’ untranslated region of NDRG1 leading to its 
suppression. Thus, the dynamic changes in NDRG1 expression and its potential 
function as a regulator of EMT and metastasis make it an attractive therapeutic target.  
In this context, iron chelators have been proposed as a possible chemotherapeutic 
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strategy due to their ability to induce NDRG1 expression (Sun et al., 2013b). Iron 
chelators are a new potential class of anti-metabolites.  In colon adenocarcinoma iron 
chelators inhibit EMT driven by TGFβ and Wnt pathways (Chen et al., 2012).   
It is important to clarify that NDRG1 likely possess tissue-specific functions.  
There is evidence of reciprocal function of NDRG1 in certain cancers.  For example, 
there are conflicting reports addressing the function of NDRG1 in gastric cancer, 
whereby one study claims that NDRG1 is a suppressor of invasion while another 
demonstrates that NDRG1 promotes angiogenesis and tumor growth (Liu et al., 2011; 
Ureshino et al., 2012). Additionally, oral cancers display extensive correlations with 
NDRG1 expression using combinatorial microarray analysis and IHC in 103 oral and 
oropharyngeal squamous cell carcinomas (Dos Santos et al., 2012). Furthermore, lung 
cancers also show positive correlation with NDRG1 expression in tumors and absence 
in normal non-neoplastic tissue (Wang et al., 2013).  NDRG1 expression in lung cancers 
promotes angiogenesis and predicts poor prognosis.   
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4. THE UBIQUITIN PROTEASOME SYSTEM 
The Ubiquitin Proteasome System (UPS) is a central node of regulation monitoring 
protein levels of virtually all signaling networks in all cells and tissues. The UPS controls 
the abundance of proteins that are critical mediators of metabolism, cell cycle 
progression, cytoskeletal changes, motility, survival and proliferation. Intracellular 
protein levels cell are regulated by the concerted action of UPS components:  ubiquitin-
activating enzymes (E1);  ubiquitin-conjugating enzymes (E2);  and ubiquitin-protein 
ligases (E3) (Lau et al., 2012).  E1, E2, and E3 enzymes cooperate to poly-ubiquitinate 
proteins leading to their degradation by the 26S proteasome (Figure 1-8).  E3 ligases 
are the enzymes responsible for protein target selection and thus the diversity of the 
UPS.  E3 ligases function as the substrate recognition domain of the UPS system to 
recognize and bind substrates intended for degradation.  There are approximately 1000 
E3 ligases in the human proteome allowing sufficient specificity to regulate the entire 
network of intracellular proteins (Lau et al., 2012).  Additionally, phosphorylation or 
hydroxylation is often required to promote E3 ligase binding.   A post-translational 
modification prerequisite facilitates precise modulation of the spatiotemporal expression 
of proteins throughout the cell cycle.  E1 enzymes activate ubiquitin through an ATP-
dependent process where the E1 enzyme forms a thiol ester bond with an ubiquitin 
molecule.  This activated form of ubiquitin is next transferred to the E2 molecule, which 
facilitates transfer of the ubiquitin to the substrate through E2 interaction with E3 
ligases.  The carboxyl-terminus of ubiquitin is bound to the epsilon-amino group of a 
lysine on the substrate (Lau et al., 2012).   
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Figure 1-8: Ubiquitin Reaction Pathways 
Initially, the E1 enzyme activates, in an ATP-dependent manner, the 76 amino acid 
ubiquitin molecule by forming a high-energy thiol ester bond with ubiquitin. This 
activated molecule is then transferred to the E2 conjugating enzyme. The E3 ligase then 
positions the target substrate near the E2 enzyme allowing for the transfer of ubiquitin. 
In the case of HECT E3 ligases however, the E3 ligase directly transfers the ubiquitin 
molecule onto the target substrate. Once a chain of four or more ubiquitin molecules is 
placed onto the substrate protein, the molecule is then targeted for proteolysis by the 26 
proteasome.  Taken from (Lau et al., 2012). 
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A single ubiquitin bound to a substrate is characterized as monoubiquitination.   A 
monoubiquitination can either lead to polyubquitination or it can instead label a protein 
for vesicular trafficking, DNA repair, or endocytosis.  There are 7 lysines in the 76 amino 
acid ubiquitin sequence that can participate in ubiquitin chain elongation.  Lys48 is the 
most well studied acceptor site leading to polyubiquitination.  A chain of 4 or more Lys48 
linked ubiquitins targets the substrate protein for proteasomal degradation by the 26S 
proteasome (Fasanaro et al., 2010).  Alternately, Lys63-linked polyubiquitination targets 
the substrate for non-proteolytic cellular processes such as DNA repair, endocytosis, 
inflammation, and translation.  Lys6, Lys11, Lys27, Lys29, and Lys33 polyubiquitination 
are less well studied and are not comprehensively understood (Zhang and Sidhu, 2013).  
Likewise, branched ubiquitination chains with multiple forms of linkage are known to 
exist, but their cellular functions are unclear. 
 
De-Ubiquitinating Enzymes 
Ubiquitination is a bi-directional system in which De-Ubiquitinating enzymes (DUBs) 
can reverse the E1-3 coordinate ubiquitin tagging by cleaving the ubiquitin moiety from 
the protein substrate (Fasanaro et al., 2010).  DUB activity may terminate non-
proteolytic functions and rescue polyubiquitinated substrates from proteolysis through 
the removal of the ubiquitin chain.  Additionally, DUBS may recycle ubiquitin from 
substrates undergoing proteolysis through the removal of ubiquitin moieties as the 
substrate enters the 26S proteasome.  DUB functions are completed by 5 subgroups of 
enzymes that include Jab1, Mov34, MPR1 Pad1 N-Terminal (JAMM)/(MPN+) 
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metalloproteases, Josephins, Ovarian tumor-like proteases (OTUs), ubiquitin C-terminal 
hydrolases (UCHs), and ubiquitin-specific proteases (USPs) (Zhang and Sidhu, 2013).  
Josephins, OTUs, UCHs, and USPs are cysteine protease DUB groups, whereas JAMM 
is the only identified metalloprotease subgroup. 
 
The 26S proteasome 
The 26S proteasome is the most common pathway for protein degradation in 
eukaryotes.  Each 26S proteasome consists of one 20S core subunit and two additional 
19S subunits.  The 20S core is assembled using 7α subunits (α1-7) and 7 β subunits 
(β1-7) (Jung and Grune, 2013).  In the ‘modern’ or eukaryotic form, the 20S core is 
composed of 4 stacked rings.  The two outer rings each consist of 7α subunits.  The α 
subunits serve structural roles and allow regulatory proteins to dock in addition to 
performing gating functions with their amino-terminal region to restrict inappropriate 
access to the core center.  The two heptameric inner rings are composed of β subunits.  
The β1-3 subunits possess active protease sites and provide the catalytic activity of the 
20S core (Jung and Grune, 2013).  Alternatively, in mammals there are a set of β 
subunits inducible by TGFα and Interferon Gamma (IFNγ) for de novo synthesis of the 
20S core (Jung and Grune, 2013).  This 20S core can bind the 11S regulatory subunit.  
Together the 20S and 11S subunits can degrade short peptides but not entire proteins.  
The lack of ATP-binding and hydrolysis likely leads to the inability to unfold complete 
proteins. 
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The 20S core is only capable of independently degrading unfolded proteins.  
Damaged and misfolded proteins can be proteolytically degraded by the β subunits 
within the 20S core.  In order to degrade folded proteins, the 20S core must bind the 
19S subunits.  The 19S regulatory subunits consist of a 9 subunit base that binds to the 
α heptameric ring and a 10 subunit lid.  6 of the 9 base subunits are ATPases 
Associated with diverse cellular Activities (AAA) ATPase units, which allow the binding 
of the 19S regulator to the 20S core(Bar-Nun and Glickman, 2012).  ATP binding to the 
hexameric AAA ATPase subunits is required for 19S and 20S binding.  ATP hydrolysis 
is only required for the unfolding of the substrate protein, but not for subunit interaction.   
 
E3 LIGASES 
The mechanism of E3 ligase ubiquitin-substrate conjugation is unique to E3 ligases.  
There are 3 primary families of E3 ligases, categorized as follows: Homologous to E6–
associated protein C-Terminus (HECT);  U-box; and Really Interesting New Gene 
(RING) domains (Fasanaro et al., 2010).  HECT E3 ligases directly conjugate the 
ubiquitin moiety to the substrate.  HECT E3s contain an active Cysteine residue that 
functions as an intermediary binding site to transfer the ubiquitin molecule to the 
substrate (Lau et al., 2012).  U-box and RING E3 ligases are scaffolding proteins that 
facilitate the co-localization of the E2 conjugating enzyme and the substrate.   
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The SCF family of E3 ubiquitin ligases 
SCF complex family of ligases is composed of the Cul1 scaffolding subunit, the Rbx 
RING subunit, the Skp1adaptor subunit, and an F-box protein that functions as the 
substrate recognition domain for the complex (Lau et al., 2012).  The F-box protein 
varies in accordance with the substrate.  The F-box subunit is the primary means to 
induce diversity in the recognition of substrates for proteolytic degradation.  The SCF 
complex contributes to the regulation of cellular processes such as cell cycle 
progression, apoptosis, and lipid metabolism.  The deregulation of the SCF complex can 
lead to carcinogenesis due to the aberrant signaling that stems from uncontrolled levels 
of pathway regulators. 
F-box proteins interact with substrates through a carboxyl-terminal protein binding 
sequence (Figure 1-9).  There are three categories of F-box proteins as defined by their 
substrate-binding sequence. F-box categories include WD40 repeats (FBXW), leucine 
rich repeats (FBXL) or other domains (FBXO) (Lau et al., 2012).   Most F-box proteins 
require post-translational modification of the substrate within a degron (phospho-
degron) to promote substrate and F-box protein interaction. 
 
FBW7 
The protein structure of F-Box and WD repeat domain-containing 7 (FBW7) contains 8 
C-terminal WD-40 repeats in addition to its WD-40 F-box motif and a D domain required 
for FBW7 dimerization (Cheng and Li, 2012).  Within the substrate binding motif there 
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Figure 1-9: SCF Family of E3 ligases 
An SCF-type E3-ligase is a multi-subunit complex consisting of three invariable subunits 
and one variable subunit. The three static subunits include a catalytic RING subunit 
(Rbx1) that interacts with the E2, a scaffolding subunit (Cul1), and an adaptor subunit 
(Skp1). The variable molecule is known as the F-box protein (FBP). The major function 
of the F-box protein is to recruit specific substrates to the E3 complex via substrate 
interaction domains. The two largest classes of interaction domains found on FBPs are 
WD40 repeats and leucine-rich repeats (LRRs). A third type of FBP also exists which 
contains neither WD40 repeats nor LRRs. This third class of F-box proteins contains 
other types of interaction domains or no recognizable domain at all. To date, there have 
been approximately 69 FBPs identified in the human genome. Furthermore, unlike 
HECT E3 ligases that can directly conjugate ubiquitin onto the target, SCF complexes 
bridge the interaction between the E2 enzyme and the substrate.  Taken from (Lau et 
al., 2012). 
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are three sequential Arg residues that interact with phosphorylated target substrates.  
The typical FBW7 phospho-degron is phosphorylated by GSK3β at a (L)-X-pT/pS-P-(P)- 
X-pS/pT/E/D sequence (Lau et al., 2012).  There are three amino-terminal splice 
variants of FBW7 (α, β, γ) that display distinct tissue and cellular localization (Cheng and 
Li, 2012).  At the cellular level FBW7α is nucleoplasmic, FBW7β is cytoplasmic, and 
FBW7γ is nucleolar.  FBW7 has been characterized as a tumor suppressor in T-cell 
Acute Lymphoblastic Leukemia (T-ALL) largely through its degradation of a large panel 
of oncogenes.  FBW7 regulation includes oncogenic substrates such as Cyclin E, C-
Myc, and Notch-1 (Wang et al., 2012).  In 6% of all human primary tumors FBXW7 is 
mutated, 43% of those cases occur within a hotspot sequence existing in the RRR 
phospho-degron binding region (Wang et al., 2012).   FBWX7 mutations affect 
numerous cellular processes and thus highlight the oncogenic potential of deregulation 
in the UPS.
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5. CONTRIBUTION OF THIS THESIS 
This thesis focuses on Akt-independent PI 3-K signaling mechanisms.  Chapter 2 
identifies a previously unknown mechanism of PI 3-K-dependent activation of SGK3.  
My studies show that INPP4B promotes SGK3 activation via its conversion of PI(3,4)P2 
to PI(3)P. This same event inhibits Akt signaling due to suppression of PI(3,4)P2. I thus 
propose that INPP4B is a signaling switch between Akt and SGK3 signaling 
downstream of PI 3-K.  These findings indicate an oncogenic capacity for INPP4B, 
which as up until now been proposed to function exclusively as a tumor suppressor.  
Chapter 2 also characterizes SGK3 and INPP4B tumorigenic phenotypes such as 
promotion of anchorage-independent growth and invasive migration under conditions of 
suppressed Akt activation.  SGK3 regulates these phenotypes in part through 
phosphorylation of NDRG1, a known metastasis suppressor and SGK-specific 
substrate.   SGK3 phosphorylation primes NDRG1 for GSK3β phosphorylation leading 
binding by FBW7.  FBW7 is the substrate recognition domain of the E3 ligase SCF 
complex, which signals NDRG1 for proteolytic degradation by the proteasome. SGK3-
induced NDRG1 degradation is a novel mechanism of PI 3-K-driven oncogenic 
signaling. 
Chapter 3 examines SGK1 and the regulation of its stability in the context of PI 3-K.  
The data reveal that Rictor, a component of the mTORC2 complex, forms a complex 
with Cullin1 to function as an E3 ligase directing SGK1 polyubiquitination and proteolytic 
degradation.  This is the first mTORC2-independent function of Rictor that has been 
identified.  Additionally, an AGC phosphorylation site on Rictor1 is identified, and 
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phosphorylation of this site leads to the disassembly of this E3 complex that functions 
as a feedback loop.   Chapter 3 elucidates a mechanism by which PI 3-K 
hyperactivation can drive SGK1 overexpression.  This SGK1 overexpression will then 
lead to hyperactivation of its substrates perpetuating the aberrant pathway signaling.   
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CHAPTER II 
SGK3 MEDIATES INPP4B-DEPENDENT PI 3-KINASE SIGNALING IN BREAST 
CANCER 
 
 
 
 
 
 
 
 
 
This chapter represents a manuscript that has been submitted for publication at Molecular Cell. 
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1.  ABSTRACT 
 
Oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of 
PI 3-K, occur with high frequency in breast cancer. The protein kinase Akt is considered 
to be the primary effector of PIK3CA, though the mechanisms by which PI 3-K mediates 
tumorigenic signals in an Akt-independent manner remain obscure. We show that the  
SGK3 is amplified in breast cancer and activated downstream of PIK3CA in a manner 
dependent on the phosphoinositide phosphatase INPP4B. Expression of INPP4B leads 
to enhanced SGK3 activation and suppression of Akt phosphorylation. Activation of 
SGK3 downstream of PIK3CA and INPP4B is required for 3D proliferation and invasive 
migration. We further show that SGK3 targets the metastasis suppressor NDRG1 for 
degradation by FBW7. We propose a model in which breast cancers harboring 
oncogenic PIK3CA and INPP4B expression activate SGK3 signaling while suppressing 
Akt, indicative of an oncogenic function for both INPP4B and SGK3 in these tumors. 
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2.  INTRODUCTION 
Somatic mutations, amplifications and other genetic lesions in genes that encode 
proteins in the PI 3-K pathway play a critical role in breast cancer etiology and 
progression by regulating phenotypes such as cell proliferation, survival and metastasis. 
The importance of PI 3-K signaling is highlighted by identification of activating 
oncogenic mutations of PIK3CA, the gene that encodes the p110α catalytic subunit of 
class I PI 3-K.  Oncogenic PIK3CA mutations are frequent in breast cancers, particularly 
in estrogen receptor positive disease where approximately 40% of cases harbor one of 
the two most frequent mutations, H1047R and E545K (Cancer Genome Atlas, 2012; 
Engelman et al., 2006; Lee et al., 2005; Samuels et al., 2004). Class I PI 3-K activate 
signaling cascades by generating the phosphoinositides PI(3,4)P2 and PI(3,4,5)P3 
(Manning and Cantley, 2007). Arguably the most studied and best understood effector 
of PI 3-K is the serine/ threonine protein kinase Akt/protein kinase B (PKB). Activation of 
Akt is initiated though interaction of the Pleckstrin homology (PH) domain with either 
PtdIns-3,4-P2 or PtdIns-3,4,5-P3 (Chin and Toker, 2009; Franke et al., 1997; Woodgett, 
2005). This is followed by phosphorylation of Akt by the PDK-1 and mTORC2 locking 
the enzyme in the catalytically competent conformation (Mora et al., 2004; Sarbassov et 
al., 2005).  
Signal termination of PI 3-K and Akt signaling is mediated by PTEN, a tumor 
suppressor protein that dephosphorylates PI(3,4,5)P3 converting it back to PI(4,5)P2 (Li 
et al., 1997; Maehama and Dixon, 1998).  LOH, inactivating mutations or deletions in 
PTEN are frequent in many cancers, and lead to excessive PI(3,4,5)P3 accumulation 
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and hyperactivation of downstream effectors, including Akt (Engelman et al., 2006).  An 
alternative mechanism of negative regulation of the Akt pathway is through the SHIP 
family of proteins that dephosphorylate PI(3,4,5)P3 and generate PI(3,4)P2, (Choi et al., 
2002; Scheid et al., 2002).  In turn, PI(3,4)P2 signaling is terminated by 
dephosphorylation, mediated by INPP4A and INPP4B, resulting in PI(3)P generation 
(Gewinner et al., 2009; Norris et al., 1997; Norris and Majerus, 1994). INPP4A and 
INPP4B both function as suppressors of Akt activity (Ivetac et al., 2009), however, 
INPP4A expression is primarily restricted to the brain while INPP4B is expressed most 
tissues, including breast (Fedele et al., 2010). 
Despite numerous studies pointing to Akt as a primary transducer of the PI 3-K 
signal, PIK3CA mutant tumors have strikingly low levels of phosphorylated (hence 
activated) Akt, indicating that other PI(3,4)P2 and PI(3,4,5)P3 effectors link PI 3-K to 
tumorigenesis (Stemke-Hale et al., 2008; Vasudevan et al., 2009). Such effectors 
include the Tec family kinases Btk and Itk (Luo et al., 2003; Miao et al., 2010). 
Moreover, GTPase activating proteins for Rho family GTPases also transduce PI 3-K 
signaling, such as GRP1 (Shiota et al., 2006). A more recent study showed that 
PIK3CA-mediated breast cancer cell growth and survival is dependent on SGK3, in 
cases where Akt was dispensable	  (Vasudevan et al., 2009).  SGK3 is an AGC protein 
kinase family member along with two other isoforms, SGK1 and SGK2. SGK isoforms 
share ~55 % sequence identity with the Akt1-3 catalytic domains (Firestone et al., 2003; 
Kobayashi et al., 1999; Tessier and Woodgett, 2006b).  SGK and Akt isoforms also 
phosphorylate the same consensus substrate motif, RXRXXS/T, and thus possess a 
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large number of shared substrates (Murray et al., 2004). SGK isoforms are also 
activated by the same upstream kinases as Akt, PDK-1 at the activation loop residue 
and TORC2 at the hydrophobic motif (Garcia-Martinez and Alessi, 2008; Kobayashi and 
Cohen, 1999; Kobayashi et al., 1999; Liu et al., 2000). As with Akt, SGK 
phosphorylation at these residues is necessary for catalytic activity.  However, unlike 
Akt, SGKs have unique regulatory regions. In the case of SGK3, this includes an amino-
terminal PX domain (Xu et al., 2001). The SGK3 PX domain binds to PI(3)P, thereby 
localizing a pool of the kinase to endosomal membranes (Tessier and Woodgett, 2006a; 
Xu et al., 2001).  
Despite the nomenclature, SGK3 expression is not regulated by glucocorticoids, 
instead ER signaling has been shown to induce SGK3 transcription (Wang et al., 2011a; 
Xu et al., 2012). Interestingly, INPP4B is also an ER-induced gene (Fedele et al., 2010). 
Luminal breast cancers are defined by their expression of estrogen and progesterone 
receptors, distinguishing them from HER2 and basal-like (triple-negative) subtypes 
(Fedele et al., 2010; Sorlie et al., 2001). INPP4B inactivation by LOH is a frequent event 
in basal-like cancers, and its loss leads to Akt hyperactivation (Cancer Genome Atlas, 
2012; Fedele et al., 2010; Gewinner et al., 2009). Conversely, INPP4B has been 
proposed to be a novel biomarker for luminal-type breast cancers, which also harbor 
frequent PIK3CA oncogenic mutations. 	  
The mechanisms linking PIK3CA to SGK3 signaling and downstream phenotypes 
have not been defined. Here we show that INPP4B mediates PIK3CA-dependent SGK3 
activation in breast cancer cells. We also show that SGK3 regulates N-Myc downstream 
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regulated 1 (NDRG1) leading to ubiquitination and degradation mediated by the E3 
ligase F-box and WD repeat domain-containing 7 (FBW7).  Finally, we show that SGK3 
functions as a PI 3-K effector in the control of oncogenic signals promoting cell growth 
and migration of breast cancer. 	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3.  MATERIALS AND METHODS 
 
Cell culture and transfection 
BT-20, DLD-1, HEK293T, HCC1937, HeLa, MDA-MB-435, MDA-MB-231, NIH/3T3 and 
MCF7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Cellgro) 
supplemented with 10% Fetal Bovine Serum (FBS; Gibco). ZR-75-1 cells were grown in 
RPMI 1640 medium supplemented with 10% FBS.  MCF10A cells were maintained in 
DMEM/Ham’s F12 medium supplemented with 5% equine serum (Cellgro), 10 µg/ml 
insulin, 500 ng/ml hydrocortisone (Sigma-Aldrich), 20 ng/ml epidermal growth factor 
(EGF) (R&D systems) and 100 ng/ml cholera toxin (List Biological Labs). T47D and BT-
549 were cultured in RPMI 1640 supplemented with 10% FBS and 10 µg/ml insulin. 
SUM159PT were grown in HAM’s F12 supplemented with 5% FBS and 5 µg/ml insulin 
and 1µg/ml hydrocortisone. Hs578T were growing in DMEM supplemented with 10% 
FBS and 0.01 mg/ml bovine insulin.  VPS34 fl/fl MEFs were provided by Wei-Xing Zong 
(Stony Brook University) and cultured as previously described (Guertin and Sabatini, 
2007). Transient transfections were performed using X-tremeGENE HP (Roche). 
 
Growth factors and inhibitors 
Cells were stimulated for 20 min with 100 ng/ml recombinant human IGF-1 (R&D 
systems).  MG132 (Cayman Chemicals) was used at 10 µM for 16 hr. Cycloheximide 
was used at 10 µg/ml. Inhibitors were as follows: BKM120, 1µM; A66, 1µM; rapamycin, 
100nM; GSK650394, 10µM; and SB415286, 25 µM. 
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Plasmids 
SGK3-GST was provided by Sandra Marmiroli (University of Modena and Reggio 
Emilia).  FLAG- p110α/ pCMV2 (#16643) FLAG-p110α H1047R/ pCMV2 (#16639) and 
FLAG-p110α E545K/ pCMV2 (#16642) plasmids were obtained from Addgene. HA-
FBW7 and HA-GSK3 were described previously (Wei et al., 2005).  NDRG1-FLAG was 
provided by Sushant Kachhap (Johns Hopkins Medical Institute) (Kachhap et al., 2007). 
pEAK-FLAG/INPP4B was provided by Lewis Cantley (Weill Cornell Medical College). 
FLAG-VPS34 was provided by Junying Yuan (Harvard Medical School). pHAGE-N-
eGFP was provided by Wade Harper (Harvard Medical School). His-Ub was previously 
published (Reiling and Sabatini, 2006). FLAG-INPP4B.C842A was generated by site- 
directed mutagenesis with the following primers: sense, 5’-
AATGGTATTCGTTTCACCTGTGCTAAAAGTGCCAAAGACAGGAC -3’; anti-sense:  5'- 
GTCCTGTCTTTGGCACTTTTAGCACAGGTGAAACGAATACCATT-3'. FLAG-1A-
NDRG1 was constructed by site- directed mutagenesis with the following primers: 346A-
sense: 5’-ACCCGCAGCCGCTCCCACGCCAGCGAGGGCA-3’; 346A-anti-sense, 5’-
TGCCCTCGCTGGCGTGGGAGCGGCTGCGGGT-3’. FLAG-8A-NDRG1 was generated 
using site- directed mutagenesis and the following primers: 328A/ 330A-sense, 5’ 
TGCGGTCCCGCGCAGCCGCTGGTTCCAGC 3’; 328A/ 330A-anti-sense, 5’ 
GCTGGAACCAGCGGCTGCGCGGGACCGCA 3’; 342A –sense, 5’ 
GATGGCACCCGCGCCCGCTCCCACGC 3’;  342A-anti-sense, 5’ 
GCGTGGGAGCGGGCGCGGGTGCCATC 3’; 352A/362A-sense, 5’ 
CGAAGCCGCTCCCACGCCAGCGAGGGCACCCGCAGCCGCTC 3’; 352A/362A-anti-
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sense, 5’ CTCGCTGGCGTGCGAGCGGCTGCGGGTGCCCTCGCTGGCGTGGGAGC 
3’; 346A-sense: 5’ ACCCGCAGCCGCTCCCACGCCAGCGAGGGCA 3’; 346A-anti-
sense, 5’ TGCCCTCGCTGGCGTGGGAGCGGCTGCGGGT 3’; 356A/366A-sense, 
5’AAGCCGCTCCCACGCCAGCGAGGGCACCCGCAGCCGCTCGCAC 3’; 356A/ 366A-
antisense, 5’ 
CTCGCTGGCGTGCGAGCGGCTGCGGGTGCCCTCGCTGGCGTGGGAGCGGCTT 3’.  
shRNA-resistant SGK3 and INPP4B were made by Gateway Cloning (Life 
Technologies) into lentiviral pHAGE-N-eGFP vector followed by site-directed 
mutagenesis.  SGK3.shRNA2-resistant SGK3-GFP (SGK3*) was generated by site-
directed mutagenesis with the following primers: sense, 5’ 
AGATTTTATTAAACAAAGACGAGCAGGACTGAATGAGTTTATTCAGAACCTAGTTAG
GTATCCAGAACTT 3’: anti-sense, 5’ 
AAGTTCTGGATACCTAACTAGGTTCTGAATAAACTCATTCAGTCCTGCTCGTCTTTG
TTTAATAAAATCT 3’. INPP4B.shRNA2-resistant INPP4B-GFP (INPP4B*) was 
generated using site-directed mutagenesis with the following primers: sense, 5’-
TTCATCCTTGCATGCAAGGATCTCGTGGCACCAGTGAGGGATCGTAAACTGAATAC
ACTGGTGC-3’: anti-sense, 5’-
GCACCAGTGTATTCAGTTTACGATCCCTCACTGGTGCCACGAGATCCTTGCATGCA
AGGATGAA-3’.  All point mutations were verified by DNA sequencing.   
 
shRNA-containing vectors: shRNA-mediated silencing of Fbw7, INPP4B, SGK3, and 
Akt1 each required the synthesis of a set of oligonucleotides composed of a target 
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shRNA sequence and its complement against each respective gene. Two hairpins were 
generated against each gene as follows:  Fbw7.shRNA1-sense, 5’-
AACCTTCTCTGGAGAGAGAAA-3’; Fbw7.shRNA1-anti-sense, 5’-
TTTCTCTCTCCAGAGAAGGTT-3’; Fbw7.shRNA6-sense, 5’-
CCAGAGACTGAAACCTGTCTA-3’; Fbw7.shRNA6-anti-sense, 5’-
TAGACAGGTTTCAGTCTCTGG-3’; INPP4B.shRNA2-sense, 5’- 
CCGGCCATCTGAGTATCCCATCTATCTCGAGATAGATGGGATACTCAGATGGTTTTT
G-3’; INPP4B.shRNA2-anti- sense, 5’-
AATTCAAAAACCATCTGAGTATCCCATCTATCTCGAGATAGATGGGATACTCAGATG
G-3’; INPP4B.shRNA6-sense, 5’-
CCGGAGATACTCCAGCACCGAAATTCTCGAGAATTTCGGTGCTGGAGTATTTTTTG-
3’; INPP4B.shRNA6-anti-sense, 5’-
AATTCAAAAAAGATACTCCAGCACCGAAATTCTCGAGAATTTCGGTGCTGGAGTATC
T-3’;  SGK3.shRNA1-sense, 5'-
CCGGGCGAGACCCTAGTTAAGAGAACTCGAGTTCTCTTAACTAGGGTCTCGCTTTT
T-3'; SGK3.shRNA1-anti-sense, 5’-
AATTCAAAAAGCGAGACCCTAGTTAAGAGAACTCGAGTTCTCTTAACTAGGGTCTC
GC-3’; SGK3.shRNA2-sense, 5’-
CCGGGCAGGACTAAACGAATTCATTCTCGAGAATGAATTCGTTTAGTCCTGCTTTTT
-3’; SGK3.shRNA2-anti-sense, 5’-
AATTCAAAAAGCAGGACTAAACGAATTCATTCTCGAGAATGAATTCGTTTAGTCCTG
C-3’; Akt1.shRNA, sense, 5′-
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CCGGGAGTTTGAGTACCTGAAGCTGCTCGAGCAGCTTCAGGTACTCAAACTCTTTT 
TG-3′; Akt1.shRNA, anti-sense, 5′-
AATTCAAAAAGAGTTTGAGTACCTGAAGCTGCTCGAGCAGCTTCAGGTACTCAAAC
TC-3′ 
 The primer sets were each annealed and ligated into pLKO.   Lentiviral supernatants 
were produced by transfection of HEK293T cells with VSVG, Δ8.2, and control-PLKO, 
Fbw7, INPP4B, or SGK3 shRNA-containing vectors for 48 hr. 
 
Antibodies 
Anti-Akt (#4685), anti-phospho-Akt Ser473 (#4060), anti-phospho-Akt Thr308 (#9275), 
anti-Cyclin E (#4129), anti-GSK3β (#9315), anti-phospho-GSK3β (#9336), anti-NDRG1 
(# 5196), anti-phospho-NDRG1 Thr346 (#3217), anti-p110α (#4249), anti-S6K (#2705), 
anti-phospho-S6K Thr389 (#9205), anti-SGK3 (#8156), anti-Vps34 (#4263) and anti-β-
actin (#4970) were purchased from Cell Signaling Technologies. Anti-FLAG M2 
(#F3165) was from Sigma-Aldrich. Anti-phospho-SGK3 Thr320 (# S1010-85W8) was 
from US Biologicals. Anti-GFP (# sc-9996), anti-GST (# sc-459) and anti-INPP4B (#sc-
12318) were from Santa Cruz. Anti-FBW7 (#A301-720A) was from Bethyl Laboratories. 
Anti-SGK3 (#LS-C132061) for immunoprecipitation was from LifeSpan BioSciences. 
Anti-HA was generated and purified from the 12CA5 hybridoma. Anti-p85 was 
generated in house and has been previously described (Kapeller et al., 1995). 
Horseradish peroxidase-conjugated anti-goat was from Millipore. Horseradish 
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peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulin G (IgG) antibodies 
were from Chemicon. 
 
In vitro protein kinase assays 
MCF7 cells infected with pLKO-control or INPP4B.shRNA-pLKO were transfected with 
SGK3-GST.  24 hr post-transfection cells were serum-starved for 16 hr followed by 20 
min stimulation with IGF-1.  SGK3 was isolated with glutathione beads and incubated 
with 75ng GST-GSK3β substrate peptide and 250 µM cold ATP in kinase assay buffer 
(Cell Signaling Technologies) for 35 min at 30°C.  The kinase reaction was terminated 
by the addition of 1x SDS-PAGE loading buffer.  Alternatively, 293T cells were co-
transfected with SGK3-GST and wild type, E545K, or H1047R PIK3CA.  SGK3 was 
precipitated and used for in vitro kinase assays as described in the above protocol. 
 
Transwell migration and invasion assays 
Transwell assays were carried out essentially as previously described (Chin and Toker, 
2010). Briefly, NIH 3T3 conditioned media was added to the lower chamber of 8 µm 
pore Transwells (Corning).  For invasion assays, filters were coated with 10 mg Matrigel 
(BD Biosciences).  10x105 cells were added to the upper chamber, in triplicate and 
migration allowed to proceed for 2-24 hr at 37°C, depending on the cell line. Cells that 
migrated or invaded to the lower chamber were fixed, stained using Hema-3® stain kit 
(Protocol; Fisher Scientific; Pittsburgh), and counted.   
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Immunoblotting  
Immunoblotting was carried out as previously described (Chin and Toker, 2010). Briefly, 
cell lysates were separated on SDS-PAGE followed electrophoretic transfer to 
nitrocellulose membranes. Membranes were blocked in 5% nonfat dry milk/TBST (10 
mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 30 min.  Blots were rinsed in 
TBST, and incubated at 4°C in primary antibody dilutions in 5% nonfat dry milk/ TBST 
for 16 hr. Membranes were then incubated with horseradish peroxidase-conjugated 
secondary antibody for 1 hr at 25°C. Membranes were rinsed in TBST and developed 
with chemiluminescence HRP substrate (Millipore). 
 
Quantitative RT-PCR analysis 
RNA was extracted using the Qiagen RNeasy. Reverse transcription reaction was 
carried out with ABI Taqman Reverse Transcriptional Reagent (N808-0234). After 
mixing the resulting cDNA template with NDRG1 (sense: 5′-
CCTGAGATGGTAGAGGGTCTC-3′ and antisense: 5′-
CCAATTTAGAATTGCATTCCACC-3′) or glyceraldehyde-3-phosphate dehydrogenase 
(sense: 5′-GCAAATTCCATGGCACCGT-3′ and antisense: 5′-
TCGCCCCACTTGATTTTGG-3′) primers quantitative RT-PCR was performed using 
SYBR Green PCR master mix in an ABI Prism 7500 sequence detector (Applied 
Biosystems, Foster City, CA). 
 
Copy number analysis 
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The algorithm GISTIC (Genomic Identification of Significant Targets in Cancer) was 
used to analyze chromosome 8 gene copy numbers of the Tumorscape database. 
Tumorscape data analysis was performed as described (Beroukhim et al., 2010).  SGK3 
GISTIC profile was generated using 3131 cell lines and tumors. GISTIC analysis for 
breast cancer was performed using 243 breast samples and a limit of Q-value < 0.250 
for focal peak amplification. Significance values were determined using the FDR (false 
discovery rate) test. 
 
3D Culture Assay 
3D cultures were performed as described (Debnath et al., 2003).  Chamber slides were 
coated with growth factor-reduced Matrigel (BD Biosciences) and allowed to solidify at 
37°C for 30 min. Subsequently, 3000 cells were seeded to each chamber slide in assay 
media (10% FBS/RPMI, 2 µg/ml puromycin, and 2% Matrigel).  The assay media was 
aspirated and replaced 4 days after seeding. Quantitation was conducted using ImageJ 
quantitation of 2D surface area on Day 8(NIH).  
 
Soft Agar Colony Formation Assay 
Soft agar assays were performed by coating 6 cm3 tissue culture plates with 5 mL of 
0.8% Noble agar / growth media (10% FBS/DMEM and 2 µg/ml puromycin) and allowed 
to solidify at 20°C.  5x104 MCF7 breast cancer cells were plated in 1 mL top layer 0.4% 
Noble agar/ growth media (10% FBS/DMEM and 2 µg/ml puromycin).  Soft agar was 
solidified at 20°C for 4 hr then transferred to 37°C incubator for the duration of the 
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assay.  Growth media (10% FBS/DMEM and 2 µg/ml puromycin) was added every 4 
days and cells were counted and measured 28 days after seeding. Quantitation was 
performed using MatLab software (MathWorks).  
 
Ubiquitination Assay 
Cell based in vivo ubiquitination assays was performed as described (Chan et al., 
2012). 293T cells were transfected with indicated plasmids for 48 hr followed by lysis in 
denatured buffer (6M guanidine-HCl, 0.1M Na2HPO4/NaH2PO4, 10 mM imidazole). The 
cell lysates were incubated with nickel beads for 3 hr, washed, and subjected to 
immunoblotting analysis. 
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4. RESULTS   
SGK3 is amplified and hyperactivated in breast cancer 
A recent study demonstrated that SGK3 is required for the survival of certain breast 
cancer cell lines with oncogenic PIK3CA mutations. These same cells showed minimal 
Akt activity and furthermore, Akt was dispensable for survival (Vasudevan et al., 2009). 
The Akt PH domain binds the PI 3-K lipids PI(3,4)P2 and PI(3,4,5)P3, however the 
SGK3 regulatory region lacks a functional PH domain. Instead, SGK3 regulation is in 
part mediated by the PX domain that primarily binds PI(3)P (Tessier and Woodgett, 
2006a). Since PI(3)P is not a product of class I PI 3-kinases, the mechanism by which 
SGK3 functions as an effector of PIK3CA remains undefined.  
Somatic activating mutations in the SGK3 gene have not been identified with 
any appreciable frequency. We examined whether amplifications or deletions of SGK3 
exist in human cancers and cancer cell lines in a published database of 3131 cancers 
(Beroukhim et al., 2010). Amplifications were present in 30% of tumors.  In 4.8% of 
cases, these were focal events encompassing less than half of chromosome 8q, a rate 
significantly above the genome-wide average (q=0.00168) (Figure 2-1).  Among the 
243 breast cancers in the study, 54% exhibited amplifications of SGK3, including 12% 
with focal alterations (q=0.186), and indeed SGK3 is one of 64 genes within the "peak 
region" where these amplifications most overlap (Figure 2-2).  Chromosome 8q also 
includes MYC, which is the most commonly amplified gene among these cancers. 
 However, the SGK3 peak was significant even after discounting amplifications which 
encompassed MYC.   
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Figure 2-1: SGK3 is amplified in cancer 
Copy-number profiles across chromosome 8 (y-axis) for 3,131 cancer samples (x-axis). 
A magnified view of the region including the SGK3 gene locus is shown in the inset.  
Analysis was performed from a data set obtained from a study of 3,131 cancers of over 
25 subtypes.  Samples are sorted by frequency of amplification at the SGK3 locus. 
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Figure 2-2: SGK3 is focally amplified in breast cancer 
Copy-number profiles from 243 breast cancers selected from the data set described in 
(Figure2-1). 
 
 
 
 
 
	   62	  
We next analyzed SGK3 protein levels in a panel of breast cancer cell lines 
informed by the Tumorscape analysis to have amplified SGK3, along with PIK3CA and 
PTEN mutation status (Table 2-1). Cells were serum-starved and stimulated with 
insulin-like growth factor-1 (IGF-1) to activate PI 3-K and Akt signaling (Figure 2-3). We 
used an antibody against the SGK3 activation loop site Thr320, targeted by PDK-1, as a 
surrogate for SGK3 activation. Concomitantly, we evaluated Akt phosphorylation at the 
activation loop residue (Thr308), also targeted by PDK-1, and hydrophobic motif 
(Ser473), phosphorylated by the TORC2 complex.  An antibody that recognizes the 
endogenous SGK3 hydrophobic motif site at Ser486 is not available. We also used total 
and phospho-NDRG1 antibodies as surrogates for the activity of SGK3, noting that 
NDRG1 is a pan-SGK substrate (Murray et al., 2004; Najafov et al., 2011). We find that 
in cells that harbor oncogenic PIK3CA mutations, SGK3 is basally phosphorylated and 
further stimulated by IGF-1 (ZR-75-1, MCF7, T47D, Figure 1C). Interestingly, in these 
same cells total levels of NDRG1 are significantly lower, and since NDRG1 is an SGK 
substrate, this suggests that phosphorylation by SGK3 may lead to NDRG1 
degradation.  
Not all breast cancer cell lines that harbor PIK3CA mutations or PTEN inactivation 
display elevated SGK3 phosphorylation (e.g., SUM159PT, BT-549) (Figure 2-3). We 
therefore considered additional PI 3-K pathway alterations that would account for SGK3 
phosphorylation. INPP4B is 4’ phosphoinositide phosphatase that exclusively 
dephosphorylates the PI 3-K lipid PI(3,4)P2, converting it to PI(3)P.  
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Figure 2-3: SGK3 expression analysis in cell lines 
Cell lysates derived from the indicated breast epithelial and cancer cell lines, serum-
starved (-) or stimulated with IGF-1 for 20 min (+) were immunoblotted (IB) with the 
indicated antibodies. 
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Table 2-1:  Table of breast cancer cell lines  
 
 
Cell line name Tissue of 
origin 
Tumorigenicity Mutation ER PR P53 HER2 Others 
BT20 Breast + PIK3CA (H1047R)  - - mutant - EGFR amplified  
BT-549 Breast + PTEN truncation  - - mutant - 
HCC1937 Breast + PTEN deletion  - - mutant - 
Hs578T Breast + PIK3R1 - - mutant - 
HRas (G12D)  
MCF10A Breast - - - WT - 
MCF7 Breast + PIK3CA (E545K)  + + WT - 
MDA-MB231 Breast + KRAS (G13D)  - - mutant - 
MDA-MB435 Breast + BRaf (V600E)  - - mutant - 
SUM159PT Breast + PIK3CA (H1047L)  - - mutant - 
T47D Breast + PIK3CA (H1047R)  + + mutant - 
ZR-75-1 Breast + PTEN missense  + - WT - 
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Loss of INPP4B by LOH is frequently observed in basal-like cancers and leads to 
elevated PI(3,4)P2 levels and in turn, Akt hyperactivation (Fedele et al., 2010; Gewinner 
et al., 2009). However, INPP4B loss is not observed in estrogen receptor-positive breast 
cancers, where PIK3CA mutations occur with the highest frequency (Cancer Genome 
Atlas, 2012). In our comparative analysis, we find that elevated SGK3 phosphorylation 
correlates directly with both elevated INPP4B expression and PIK3CA mutation status 
(Figure 2-3).   
To provide cause-and-effect evidence for SGK3 as a PI 3-K effector, we used 
pathway inhibitors in cells with PIK3CA mutation and high INPP4B, as well as robust 
SGK3 phosphorylation. Since phosphorylation-state antibodies such as pThr320 (for 
SGK3) or pThr308 and pSer473 (for Akt) do not directly measure protein kinase activity, 
we developed a kinase assay to measure SGK3 activity. Endogenous SGK3 was 
immunoprecipitated and used in in vitro kinase assays with a peptide substrate derived 
from GSK-3β that is a defined optimal Akt and SGK substrate, since they share a similar 
consensus phosphorylation motif (Murray et al., 2004). Using this assay, we show that 
SGK3 activity is stimulated by IGF-1, concomitant with increased Thr320 
phosphorylation and increased NDRG1 phosphorylation (Figure 2-4). SGK3 activation 
is attenuated by both BKM-120 and A66, pan class I and p110α specific inhibitors, 
respectively (Buonamici et al., 2010; Jamieson et al., 2011). Conversely, inhibition of 
TORC1 using Rapamycin does not block SGK3 activation, consistent with the notion 
that SGK isoforms are TORC2 targets (Garcia-Martinez and Alessi, 2008). A  
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Figure 2-4: inhibitor analysis of SGK3 signaling 
T47D cells were serum-starved for 24 hr, then pretreated with the invocated inhibitors, 
rapamycin (100nM), A66 (1µM) or BKM120 (1µM) for 20 min, then stimulated with IGF-1 
for a further 20 min. SGK3 was immunoprecipitated with anti-SGK3 and subjected to an 
in vitro kinase assay (IVK) using GSK-3β peptide substrate. Peptide substrate 
phosphorylation was detected using anti-GSK-3β phospho-antibody. SGK3 
phosphorylation was detected using anti-SGK3 pT320. Total SGK3 was evaluated as 
control. Whole cell lysates (WCL) were immunoblotted with the indicated antibodies. All 
results are representative of at least 3 independent experiments. 
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requirement for PIK3CA in SGK3 activation is further substantiated by the fact that both 
basal and IGF-1-stimulated SGK3 activity is enhanced in cells ectopically expressing 
wild-type and oncogenic PIK3CA mutants (Figure 2-5). Collectively, these data 
demonstrate that SGK3 is amplified in breast cancer and its activity is dependent on 
oncogenic PI 3-K signaling. 
 
INPP4B regulates SGK3 activation 
PtdIns-3-P directly binds to the SGK3 PX domain (Tessier and Woodgett, 2006a).  
Since high INPP4B levels correlate with the ability of IGF-1 to stimulate SGK3 in 
PIK3CA mutant cells (Figure 2-3), and INPP4B generates PI(3)P, we reasoned that 
INPP4B levels are rate-limiting for SGK3 activation downstream of PI 3-K. SGK3 activity 
measured by in vitro kinase assay is significantly enhanced in cells co-expressing 
INPP4B, whereas Akt phosphorylation is attenuated, as expected (Figure 2-6).  
Moreover, endogenous SGK3 phosphorylation is also stimulated by expression of wild-
type INPP4B, but not by a catalytically- inactive phosphatase mutant (Figure 2-7). 
Although the primary route of PI(3)P synthesis is through the class III PI 3-K VPS34, 
expression of an active VPS34 allele does not promote SGK3 phosphorylation (Figure 
2-7). Moreover, VPS34 null MEFs (fl/fl) display the same level of IGF-1-stimulated 
SGK3 and NDRG1 phosphorylation as control cells (Figure 2-8).  
Silencing INPP4B using lentiviral shRNA completely attenuates SGK3 
phosphorylation in response to IGF-1, with a concomitant decrease in phospho-NDRG1  
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Figure 2-5: Oncogenic PIK3CA mutants hyperactivate SGK3 
HEK293 cells were transfected with SGK3-GST alone or in combination with 
PIK3CA.WT, PIK3CA.H1047R, or PIK3CA.E545K followed by 24 hr serum- starvation 
before stimulation with IGF-1.  Glutathione agarose was used to isolate SGK3 prior to 
incubation with GST-GSK3β peptide in an in vitro kinase (IVK) assay.  Whole cell 
lysates (WCL) and in vitro kinase assay were immunoblotted as indicated. 
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Figure 2-6: INPP4B positively regulates SGK3 activity 
HeLa cells were transfected with SGK3-GST alone or with INPP4B and serum-starved 
for 24 hr, prior to stimulation with IGF-1 for 20 min. SGK3 was isolated from cell lysates 
with glutathione beads, and incubated with GST-GSK3β peptide in an in vitro kinase 
assays (IVK). Peptide substrate phosphorylation was detected using anti-GSK-3β 
phospho-antibody. Total SGK3 was evaluated as control. Whole cell lysates were 
immunoblotted with the indicated antibodies. 
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Figure 2-7: INPP4B catalytic activity specifically promotes SGK3 phosphorylation 
HEK293T cells were transfected with wild-type INPP4B, catalytically-inactive 
INPP4B.C842A or VPS34, then serum-starved for 24 hr and stimulated with IGF-1 for 
20 min.  Whole cell lysates were immunoblotted with the indicated antibodies. IB: INPP4B!
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Figure 2-8: VPS34 loss does not affect SGK3 phosphorylation 
 
VPS34 fl/fl MEFs were infected with control (CTL) or Cre adenovirus. Control and 
VPS34-null MEFs were starved for 18 hr and stimulated for 20 min with IGF-1.  Whole 
cell lysates were immunoblotted with the indicated antibodies. 
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(Figure 2-9). Similarly, reduced SGK3 phosphorylation induced by INPP4B silencing is 
rescued by expression of an shRNA-resistant INPP4B allele (Figure 2-10). Inhibition of 
both exogenous and endogenous SGK3 protein kinase activity is also observed in cells 
transduced with INPP4B shRNA (Figure 2-11). We conclude that INPP4B is required 
for the ability of PI 3-K to activate SGK3, and that the phosphatase activity of INPP4B is 
essential. Moreover, we propose that VPS34 is dispensable for PIK3CA-mediated 
SGK3 activation.   
 
SGK3 promotes proliferation in 3D and anchorage independence of growth 
To explore the functional significance of SGK3 downstream of PIK3CA, we 
investigated the ability of SGK3 and INPP4B to drive anchorage independent growth, 
since PIK3CA has been shown to promote this phenotype (Isakoff et al., 2005).  MCF7 
cells (PIK3CA E545K, high SGK3 and high INPP4B, Figure 2-3) were transduced with 
vector control, or two distinct SGK3 and INPP4B shRNA’s, and colonies allowed to form 
(Figure 2-12A and 2-12C).  Whereas control cells form robust colonies in soft agar, 
silencing either SGK3 or INPP4B significantly inhibits the number of colonies growing in 
an anchorage-independent manner (Figure 2-12B). Additionally, introduction of shRNA-
resistant SGK3 and INPP4B cDNAs partially rescues the defect in anchorage-
independent growth (Figure 2-12). Representative images of each condition are shown 
in Figure 2-12A. 
Growth of cancer cells in 3 dimensional (3D) culture more faithfully recapitulates 
phenotypes that control tumor growth in vivo (Debnath and Brugge, 2005).  
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Figure 2-9: INPP4B silencing attenuate SGK3 phosphorylation 
 
ZR-75-1 cells were infected with shRNA lentivirus targeting INPP4B, or control pLKO, 
serum-starved and stimulated with IGF-1 for 20 min. Cell lysates were immunoblotted 
with the indicated antibodies.  
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Figure 2-10: shRNA-resistant INPP4B allele rescues SGK3 phosphorylation 
MCF7 cells were infected shRNA lentivirus targeting INPP4B, followed by retroviral 
infection with INPP4B cDNA rescue virus . Cell lysates were immunoblotted with the 
indicated antibodies.  All results are representative of at least 3 independent 
experiments. 
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Figure 2-11:  INPP4B silencing inhbits SGK3 activity 
(A) MCF7 cells were infected with INPP4B.shRNA2 prior to transfection with SGK3-
GST.  Cells were serum-starved for 18 hr before stimulation with IGF-1. Glutathione 
agarose beads were used to isolate SGK3 from cell lysates, and incubated with GST-
GSK3β in an in vitro kinase (IVK) assay. 
(B) T47D cells were infected with SGK3.shRNA2 and INPP4B.shRNA2 prior to serum-
starvation for 18 hr prior to IGF-1 stimulation.  SGK3 antibody was used to 
immunoprecipitate SGK3 for 2 hr.  In vitro kinase (IVK) assay was then performed with 
isolated SGK3 and GST-GSK3β peptide.  Whole cell lysates (WCL) were immunoblotted 
with the indicated antibodies. 
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Figure 2-12: SGK3 promotes anchorage independent growth 
(A) MCF7 cells infected with pLKO vector control, or two distinct INPP4B and SGK3 
shRNA lentiviral vectors and grown in agar/growth media for 28 days. Additional 
conditions included retroviral infection of INPP4B (INPP4B*) and SGK3 (SGK3*) cDNA 
rescue virus. Representative images of culture dishes used for the analysis in (B and C) 
Results are representative of at least 3 independent experiments. 
(B) Number of colonies in soft agar obtained in (A) was quantitated using MatLab.  
(C) Western blot analysis of MCF7 cells with indicated antibodies. 
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3D Matrigel growth of ZR-75-1 breast cancer cells (PTEN missense, high SGK3, high 
INPP4B) is also significantly attenuated upon silencing either SGK3 or INPP4B with 2 
distinct shRNA sequences each (Figure 2-13A, 2-13B, and 2-13C). Inhibition of 3D 
Matrigel growth upon SGK3 or INPP4B silencing is also observed in MCF7 cells (Figure 
2-14).  
 
SGK3 promotes breast cancer cell invasive migration 
Signaling through PIK3CA also modulates breast cancer cell migration and invasion, 
pre-requisite phenotypes for metastatic dissemination of tumor cells (Pang et al., 2009). 
We therefore examined if SGK3 is required for breast cancer cell invasive migration. 
Using in vitro Transwell migration assays, we first evaluated SUM159PT cells that 
express low levels of endogenous SGK3 (Figure 2-3). Ectopic expression of SGK3 
robustly enhances SUM159PT cell migration (Figure 2-15A). Conversely, silencing 
SGK3 with shRNA significantly attenuates MCF7 cell migration (Figure 2-15B). A 
catalytic small molecule pan-SGK inhibitor, GSK650394 (Sherk et al., 2008) also 
significantly blocks MCF7 cell migration (Figure 2-15C). Finally, ectopic expression of 
SGK3 also promotes invasive migration through Matrigel (Figure 2-15D). Therefore, 
SGK3 kinase activity is both necessary and sufficient to promote invasive migration of 
breast cancer cells.   
 
SGK3 mediates NDRG1 proteolytic processing  
Finally, since NDRG1 is an established metastasis suppressor and is also an SGK 
substrate (Kachhap et al., 2007; Murray et al., 2004; Najafov et al., 2011), we evaluated  
	   78	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-13: SGK3 regulates 3D growth of breast cancer cells 
 
(A) ZR-75-1 cells were infected with control pLKO or two distinct SGK3 shRNA or 
INPP4B shRNA’s and grown for 8 days in 3D Matrigel/cell culture media. 
Representative images spheroids at 4x magnification are shown. 
(B) Quantitation of 2D spheroid size from (A) was performed using ImageJ software. 
Error bars represent mean ± SEM. *P < 0.05 ; **P < 0.01; ***P < 0.001. Results are 
representative of at least 3 independent experiments. 
(C) Western blot analysis of 3D culture ZR-75-1cell lysates with indicated antibodies. 
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Figure 2-14: SGK3 regulates 3D growth of PIK3CA mutant breast cancer cells 
MCF7 cells were infected with control pLKO or one of two distinct SGK3 or INPP4B 
shRNA lentivirus and grown for 8 days in 3D Matrigel/culture media. Representative 
spheroid images for each condition are shown at 4X magnification. 
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Figure 2-15: SGK3 promotes breast cancer cell invasive migration 
(A) SUM159PT breast cancer cells were infected with SGK3 or control pLEGFP-N1 and 
followed by 2 hr migration through Transwell assays. Relative migration is measured 
along the Y-axis as the ratio of migrated cells in the test condition versus the control 
condition. 
(B) MCF7 breast cancer cells were infected with SGK3 shRNA lentiviral vector or control 
empty vector for 48 hr followed by Transwell migration assays. 
(C)  MCF7 cells were inhibited with SGK inhibitor, GSK650394 (10uM), or control DMSO 
for 20 min prior to Transwell migration assays. 
(D) HS578T breast cancer cells were infected with SGK3 of control pLEGFP-N1 
followed by Transwell Matrigel invasion assays. 
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the mechanism by which SGK3 controls NDRG1 stability. We initially noted a correlation 
of NDRG1 protein levels and SGK3 phosphorylation (Figure 2-3). Consistent with this, 
silencing SGK3, but not Akt1, results in a decrease in phosphorylated NDRG1 
(pThr346), with a concomitant increase in total NDRG1 (Figure 2-16A). A 
cycloheximide chase experiment reveals that the half-life of NDRG1 in serum-containing 
media is approximately 1 hour (Figure 2-16B). We also examined NDRG1 protein 
stability in cells treated with a proteasome inhibitor, and find that NDRG1 levels are 
dramatically enhanced upon inhibition of the 26S proteasome with MG132 (Figure 2-
16C). Curiously, in T47D cells, NDRG1 levels are not affected by MG132. T47D cells 
are PIK3CA H1047R mutant, have high SGK3 and INPP4B, and moreover are FBXW7 
null (Mao et al., 2008). FBW7 is an F-box E3 ubiquitin ligase and substrate recognition 
domain of the SKP1-cullin-F-box (SCF) ubiquitin ligase complex.  To determine whether 
FBW7 mediates SGK3-dependent NDRG1 degradation, we first used wild-type and 
FBW7 null DLD-1 colon carcinoma cells (Rajagopalan et al., 2004). FBW7 deletion 
leads to a dramatic increase in NDRG1 protein levels, compared to wild-type cells, 
whereas NDRG1 message levels remain unchanged (Figure 2-17A and Figure 2-17B). 
Moreover, silencing of FBW7 using two distinct shRNA sequences leads to significantly 
increased NDRG1 protein levels compared to control cells (Figure 2-18A). Increased 
NDRG1 levels upon FBW7 silencing are also observed in a distinct breast cancer cell 
line, BT-20 (Figure 2-18B). Importantly, the fold increase in NDRG1 is comparable to 
that observed with Cyclin E, a known FBW7 substrate (Figure 2-18A).   
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Figure 2-16: NDRG1 is degraded by the 26S proteasome 
(A) MCF7 cells infected with SGK3. shRNA, Akt1. shRNA or control pLKO, serum-
starved then stimulated with IGF-1 for 20 min.  Cell lysates were immunoblotted with the 
indicated antibodies. 
(B) MCF10A cells were treated with cycloheximide or control DMSO for the indicated 
times and cell lysates immunoblotted with anti-NDRG1 and anti-p85. 
(C) T47D, MCF10A, MCF7, and ZR-75-1 cells were treated with MG132 for 16 hr and 
immunoblotted with anti-NDRG1 and anti-p85. 
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Figure 2-17: FBW7 regulates NDRG1 expression at the protein level 
(A) Cell lysates of wild-type (FBW7 WT) or DLD-1 colon cancer cells null for Fbw7 
(Fbw7 -/-) were immunoblotted with the indicated antibodies. 
(B) Quantitative RT-PCR analysis to determine the relative mRNA expression of 
NDRG1 in wild-type or Fbw7-/- DLD-1 cell lines.   
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Figure 2-18: Fbw7 regulates NDRG1 protein levels in breast cancer cells 
(A) MCF7 cells were infected with two distinct Fbw7 shRNA’s or control pLKO, and 
lysates immunoblotted with the indicated antibodies 
(B) BT-20 cells were infected with two distinct Fbw7 shRNA or control pLKO, and cell 
lysates were immunoblotted with the indicated antibodies 
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Studies have shown NDRG1 phosphorylation by SGK3 at Thr346/Thr356/Thr366 
primes for phosphorylation by GSK-3β at Ser342/Ser352/Ser462 (Murray et al., 2004). 
GSK-3β phosphorylation is a common priming event for FBW7 substrate binding (Wang 
et al., 2011b).  To assess whether NDRG1 stability is dependent on the concerted 
action of SGK3, GSK-3β and FBW7, we co-expressed each component in combination 
and measured NDRG1 stability. Maximal NDRG1 degradation is only observed when 
both SGK3 and GSK-3β are simultaneously co-expressed with FBW7 (Figure 2-19A). 
Treatment of cells with SGK inhibitor, GSK650394, or GSK3 inhibitor, SB415286, 
conversely causes an increase in NDRG1 levels, while dual treatment with both 
GSK650394 and SB415286 heightens NDRG1 stability even further (Figure 2-19B). 
Finally, we used an established, cell-based ubiquitination assay to evaluate NDRG1 
ubiquitination. NDRG1 ubiquitination is increased when FBW7 is co-expressed, and 
ubiquitination is maximal when SGK3 and GSK-3β are co-expressed. In the absence of 
MG132, NDRG1 ubiquitination is completely eliminated. Furthermore, NDRG1 
ubiquitination is significantly attenuated in a mutant that lacks SGK3 and GSK-3β 
consensus phosphorylation sites. Therefore, NDRG1 stability is regulated by SGK3 
activity and subsequent FBW7-mediated degradation. To address FBW7 binding to 
NDRG1 a GST-binding assay was performed.  NDRG1.T346A has reduced ability to 
bind FBW7-GST and the 8A-NDRG1 eliminates binding to FBW7, demonstrating SGK3 
and GSK3 phosphorylation is necessary for FBW7 binding (Figure 2-20B).  In order to 
determine the phenotypic significance of SGK3 regulation of NDRG1 we investigated 
the ability of  
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Figure 2-19: GSK3 and SGK3 have additive effects on NDRG1 degradation 
(A) HEK293T cells were transfected with control GFP vector, alone or with the indicated 
combinations of NDRG1-FLAG, HA-Fbw7, HA-GSK3β.S9A and SGK3-GST. NDRG1 
stability was evaluated by immunoblotting whole cell lysates with anti-FLAG, and 
indicated antibodies.  
(B) HEK293T cells were transfected for 48 hr with NDRG1-FLAG prior to 5 hr treatment 
with GSK650394, SB415286, GSK650394 and SB415286, or MG132 in order to 
examine NDRG1 protein stability changes.   
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Figure 2-20: NDRG1 is an FBW7 substrate  
(A) A His-Ubiquitin assay was performed after transfection of HEK293T cells with 
FLAG-NDRG1, GST-Fbw7, HA-GSK3β.S9A, SGK3-GFP, and His-Ub, followed by 
treatment with MG132 for 12 hr.  Nickel NTA beads were used to isolate His-ubiquitin 
complexes, followed by immunoblotting with the indicated antibodies.  
(B) HEK293 were transfected with GST-Fbw7 and NDRG1, 8A-NDRG1, or 
NDRG1.T346A and treated with MG132 for 18 hr.  Glutathione agarose was used to 
isolate Fbw7 and associated proteins.  Pulldown and whole cell lysates (WCL) were 
immunoblotted with the indicated antibodies. 
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NDRG1 to mediate migration.  In ZR-75-1 cells the expression of NDRG1 dramatically 
inhibits Transwell cellular migration, while co-expression with SGK3, GSK3β, and FBW7 
causes a dramatic increase in migration rescuing the NDRG1 suppression of motility 
(Figure 2-21). We therefore argue that NDRG1 degradation provides a significant 
contribution to the SGK3 downstream signaling. 
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Figure 2-21: NDRG1 inhibits breast cancer cell migration 
ZR-75-1 cells were transfected for 24 hr with pcDNA3, NDRG1, or NDRG1, Fbw7, 
GSK3β, and SGK3 followed by an 18 hr Transwell migration assay. 
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5.  DISCUSSION  
The frequency of PI 3-K pathway mutations in many human solid tumors, including 
breast cancer, has led to the development of numerous small molecule inhibitors 
currently in phase I and II clinical trials (Baselga, 2011). These include inhibitors to 
PIK3CA, such as the pan class I PI 3-K inhibitor BKM-120, as well as p110α-specific 
inhibitors such as BYL-719 and A66. Various Akt catalytic inhibitors are also undergoing 
pre-clinical validation for many tumor types (Cleary and Shapiro, 2010; Courtney et al., 
2010).  Arguably, most studies that have evaluated the mechanism by which PI 3-
kinases transduce signals to phenotypes associated with malignancy have focused on 
Akt as the effector molecule. However, other PI 3-K targets have been shown to signal 
downstream of PI(3,4,5)P3, for example the Tec family kinases such as Btk in 
hematological malignancies (Davids and Brown, 2012). A more recent study pointed to 
SGK3 as a critical effector of oncogenic PIK3CA-mutant breast cancer cells in which Akt 
is dispensable (Vasudevan et al., 2009). This finding provides insight into an additional 
target for the development of new drugs for combination therapy in PI 3-K pathway 
mutant tumors.  
Since SGK3 does not possess a PH domain in the regulatory region that would bind 
PI(3,4,5)P3, the mechanism by which PIK3CA can activate SGK3 has remained 
obscure (Tessier and Woodgett, 2006b). We reasoned that such a mechanism would 
have to take into account the lipid-binding property of the SGK3 PX domain, which bind 
PI(3)P (Tessier and Woodgett, 2006a). Although PI 3-K has been shown to activate 
SGK isoforms through PDK-1 and TORC2 (Garcia-Martinez and Alessi, 2008), it has 
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also been shown that a PX domain lipid-binding mutant of SGK3 is catalytically inactive 
(Tessier and Woodgett, 2006a). This same PX domain mutant is not phosphorylated at 
the corresponding Thr320 and Ser486 sites, indicating PI(3)P binding as a pre-requisite 
for phosphorylation and activation. Since class I PI 3-kinases do not synthesize PI(3)P 
directly, an intermediate step(s) is required for SGK3 activity. Our data show that 
INPP4B is both necessary and sufficient to transduce the PIK3CA signal to SGK3 
activation. INPP4B is a PI(3,4)P2 phosphatase, such that inactivation of INPP4B by 
LOH in human tumors leads to Akt hyperactivation (Fedele et al., 2010; Gewinner et al., 
2009). Conversely, one would predict that in tumors with normal or elevated expression 
of INPP4B, the synthesis of PI(3)P would promote the activation of an alternative 
effector(s). We propose that SGK3 is one such effector, whose activation by PIK3CA is 
mediated by INPP4B in breast cancer cells. This model is supported by several lines of 
evidence. First, breast cancer cell lines with high INPP4B levels show elevated SGK3 
phosphorylation and activity, whereas lines with low or undetectable INPP4B do not 
(Figure 1C). Expression of catalytically active, but not inactive INPP4B leads to 
activation of SGK3 with a concomitant inhibition of IGF-1-stimulated Akt phosphorylation 
(Figure 2A). Moreover, silencing INPP4B with shRNA attenuates SGK3 activation, and 
also leads to inhibition of anchorage-independent growth and proliferation in 3D (Figure 
2-9, Figure 2-12 and Figure 2-13). In a previous study, silencing INPP4B with shRNA 
was shown to result in increased anchorage-independent growth, also in MCF7 cells 
(Fedele et al., 2010). The reason for the discrepancies between the two studies is 
unclear, but could be due to differences in shRNA sequences used. In our studies, two 
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distinct shRNA sequences were used, and introduction of INPP4B cDNA rescued the 
phenotype. Regardless, our data support a model in which INPP4B functions as both an 
oncogene and a tumor suppressor. A tumor suppressor function is evident in basal-like 
tumors, which show a high frequency of INPP4B LOH, and a concomitant increase in 
Akt activity (Fedele et al., 2010). Conversely, an oncogenic role for INPP4B is supported 
by breast cancer cell lines derived from luminal tumors that show elevated SGK3 
activation and high INPP4B expression.  
INPP4B dephosphorylates PI(3,4)P2 to generate PI(3)P, and our results show that 
INPP4B catalytic activity is required for SGK3 activation. Since the SGK3 PX domain 
binds PI(3)P, this would argue that SGK3 activation would occur at sites of PtdIns-3-P 
accumulation. PI(3)P is also be generated by class I and II PI 3-kinases. Specifically, a 
significant pool of PI(3)P is generated by the class III enzyme VPS34 at endosomal 
membranes (Backer, 2008). Previous studies have shown that SGK3 is localized at the 
endosome in a manner that depends on an intact PX domain (Tessier and Woodgett, 
2006a). Since SGK3 phosphorylation and subsequent activation are dependent on a 
functional PX domain, this would argue that SGK3 activation occurs primarily at the 
endosome. However, in our studies we find that PIK3CA-mediated activation of SGK3 
does not require VPS34 (Figure 2-8). The products of PIK3CA, PI(3,4,5)P3 and 
PI(3,4)P2 are synthesized primarily at the plasma membrane, indicating that the pool of 
PI(3)P generated by INPP4B would also reside at the plasma membrane. In turn, a 
plasma membrane pool of PI(3)P would recruit SGK3 leading to its activation. Although 
we cannot formally rule out that the PI(3)P generated by INPP4B recruits SGK3 at the 
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endosome, this is unlikely because studies have demonstrated that the endosomal 
recruitment of SGK3 is PI 3-K-independent (Tessier and Woodgett, 2006a). Tools for 
detecting endogenous SGK3 localization, such as activation-state antibodies, are not of 
sufficient sensitivity for use in immunofluorescence or immunohistochemistry, and to 
date our results aimed at localizing SGK3 in response PI 3-K and INPP4B signaling 
have been inconclusive. Future studies using more specific reagents will be required to 
address the relevant localization of SGK3 downstream of PIK3CA.  
Oncogenic PIK3CA mutations are particularly prevalent in ER-positive breast 
cancers (Cancer Genome Atlas, 2012). Interestingly, INPP4B has been identified as a 
potential biomarker for luminal-type breast cancers (Fedele et al., 2010). Moreover, both 
INPP4B and SGK3 are transcriptionally regulated by estrogen (Harvell et al., 2006; 
Wang et al., 2011a; Xu et al., 2012). This suggests that the PIK3CA/INPP4B/SGK3 
signaling axis is particularly important at promoting tumorigenesis in hormone receptor-
positive cancers. It is also interesting to note that the original characterization of SGK3 
as a required target for PIK3CA-mediated growth and survival was conducted MCF7 
cells, which express estrogen receptor (Vasudevan et al., 2009). Whether ER 
expression is necessary or rate- limiting for the PIK3CA/INPP4B/SGK3 pathway 
remains to be determined, since other mechanisms contribute to the transcriptional 
induction of both INPP4B and SGK3.  
The majority of SGK3 substrates identified to date have also been shown to be 
phosphorylated by Akt, and thus likely share overlapping phenotypes during tumor 
progression (Tessier and Woodgett, 2006b). However, NDRG1 is the only known 
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specific SGK substrate, although the functional consequence of SGK-mediated 
phosphorylation of NDRG1 is not known. We explored NDRG1 as a target of SGK3 in 
breast cancer cells, since NDRG1 is a known metastasis suppressor and its expression 
inversely correlates with breast cancer grade (Kovacevic and Richardson, 2006). Our 
results show that SGK3 is required for invasive migration, a pre-requisite for metastatic 
dissemination (Figure 2-15). We also find that NDRG1 protein levels are inversely 
correlated with SGK3 activity, suggesting that SGK3 might control NDRG1 stability 
(Figure 2-3). It has been shown that SGK3 phosphorylation of NDRG1 primes for 
subsequent phosphorylation by GSK3β (Murray et al., 2004).  Our studies provide 
additional insight into NDRG1 regulation, as we show that SGK3 and GSK-3β control 
the interaction of NDRG1 with the substrate recognition domain of the E3 ligase SCF 
complex, FBW7 (Figure 2-19 and Figure 2-20). FBW7 targets NDRG1 for degradation 
by the 26S- proteasome. In turn, loss of NDRG1 expression is known to reduce the 
recycling of E-cadherin to the plasma membrane, increase cell migration and eventual 
metastatic dissemination (Kachhap et al., 2007). Consistent with this, we find that 
silencing SGK3 inhibits cell migration, an effect that is phenocopied by expression of 
NDRG1 (Figure 2-15 and Figure 2-21). In this model, PIK3CA-mutant tumor cells with 
elevated SGK3 activity would maintain low NDRG1 levels, resulting in enhanced 
invasive migration.  
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6.  CONCLUSION 
In summary, we have identified a new mechanism by which PIK3CA transduces 
tumorigenic phenotypes in breast cancer, specifically though SGK3 activation. INPP4B 
catalytic activity is required for the ability of breast cancer cells with oncogenic PIK3CA 
to activate SGK3. This provides an alternative mechanism for PIK3CA to drive cancer 
progression under conditions in which Akt is inactive. These findings advocate for the 
development of small molecule inhibitors targeting SGK3, for PIK3CA-addicted tumors 
resistant to Akt inhibition.  
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CHAPTER III 
RICTOR FORMS A COMPLEX WITH CULLIN-1 TO PROMOTE SGK1 
UBIQUITINATION AND DESTRUCTION 
 
 
 
 
 
 
 
This chapter is abstracted from a manuscript that has been published in Molecular Cell: 
 
Gao D, Wan L, Inuzuka H, Berg AH, Tseng A, Zhai B, Shaik S, Bennett E, Tron 
AE, Gasser JA, Lau A, Gygi SP, Harper JW, DeCaprio JA, Toker A, Wei W. Rictor 
forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol 
Cell. 2010 Sep 10;39(5):797-808. 
 
J.Gasser contributed unpublished data which initiated the investigations on which the manuscript is 
based.  The data from J.Gasser showed SGK1 stability changes upon IGF-1 simulation and 26S 
proteasome inhibition.  Additionally, J. Gasser contributed a number of SGK1 reagents to the manuscript. 
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1.  ABSTRACT 
 
The Rictor/mTOR complex (also known as mTORC2) plays a critical role in 
cellular homeostasis by phosphorylating AGC kinases such as Akt and SGK at their 
hydrophobic motifs to activate downstream signaling. However, the regulation of 
mTORC2 and whether it has additional function(s) remains largely unknown. Here we 
report that Rictor associates with Cullin-1 to form a functional E3 ubiquitin ligase. Rictor, 
but not Raptor or mTOR alone promotes SGK1 ubiquitination. Loss of Rictor/Cullin-1-
mediated ubiquitination leads to increased SGK1 protein levels as detected in Rictor null 
cells. Moreover, as part of a feedback mechanism, phosphorylation of Rictor at T1135 
by multiple AGC kinases disrupts the interaction between Rictor and Cullin-1 to impair 
SGK1 ubiquitination. These findings indicate that the Rictor/Cullin-1 E3 ligase activity is 
regulated by a specific signal relay cascade and that misregulation of this mechanism 
may contribute to the frequent overexpression of SGK1 in various human cancers. 
 
(Gao et al., 2010) 
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2.  INTRODUCTION 
The mammalian target of Rapamycin (mTOR) plays a critical role in regulation of 
cellular homeostasis, cell growth and survival pathways by acting as a sensor for 
upstream inputs from multiple growth-promoting signals which are then transduced to 
downstream effectors (Guertin and Sabatini, 2007; Reiling and Sabatini, 2006).  In order 
to fulfill this complex regulatory function, the mTOR kinase assembles into at least two 
distinct complexes termed mTORC1 and mTORC2 (Guertin and Sabatini, 2007; Reiling 
and Sabatini, 2006).  These two multi-component subcomplexes differ both structurally 
and functionally and signal to distinct downstream substrates. mTORC1 is composed of 
mTOR, Raptor, PRAS40 and mLST8/GβL (G protein β-subunit-like protein). The best 
characterized mTORC1 kinase substrates include S6K (p70 S6 ribosomal kinase) and 
4E-BP1 (phosphorylated 4E-binding protein). The mTORC2 complex includes mTOR, 
Rictor, mLST8/GβL, PROTOR (protein observed with Rictor-1)/PRR5 and Sin1 (Jacinto 
et al., 2006; Shiota et al., 2006). mTORC2 phosphorylates the hydrophobic motif of Akt 
at Ser473 (Sarbassov et al., 2005)and SGK1 at Ser422 (Garcia-Martinez and Alessi, 
2008), leading to full kinase activation. Since aberrant activation of Akt is a hallmark of 
many types of cancers (Manning and Cantley, 2007), hyperactivation of mTORC2 
activity has been implicated in cancer progression (Guertin and Sabatini, 2007). 
 
The activity of the mTORC1 complex is highly regulated in cells exposed to 
growth factors and nutrients. In response to mitogens, activation of PI 3-K leads to 
phosphorylation of the TSC2 and PRAS40 proteins by Akt, culminating in activation of 
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mTORC1 (Manning and Cantley, 2007).  The activity of mTORC1 can also be 
stimulated by the Rag GTPase in response to nutrient stimulation (Sancak et al., 2008).  
Additionally, phosphorylation of Raptor by AMPK (5′ AMP-activated protein kinase) in 
response to a low energy state provides a negative regulatory mechanism to repress 
mTORC1 activity (Gwinn et al., 2008). Although mTORC2 is a key upstream kinase 
complex that functions to control Akt phosphorylation and downstream signaling, 
relatively little is known regarding the regulation of mTORC2. Recent studies indicate 
that the mTOR complexes might be multi-functional and contain activities other than 
protein kinases. For example, Raptor has been shown to form a complex with the Cullin-
4 E3 ligase and this complex might be critical for mTOR kinase activity (Ghosh et al., 
2008).  Rictor has also been shown to associate with Cullin-4, although unlike Raptor it 
is not a WD40-repeat-containing protein (Ghosh et al., 2008).  However, additional 
function(s) for Rictor and mTORC2 remain largely unknown. 
 
The serum and glucocorticoid-inducible kinase (SGK) belongs to the AGC 
(protein kinase A, G and C) family of kinases, and its activity is stimulated by growth 
factors (Lang et al., 2006). There are three closely related family members designated 
SGK1, SGK2 and SGK3 (Loffing et al., 2006). One of the best-characterized SGK1 
downstream targets is Foxo3a, which is involved in the regulation of apoptosis (Brunet 
et al., 2001). SGK1 has also been indicated in the regulation of Na+ retention through 
phosphorylation of NEDD4-2 to impair its ability to degrade the epithelial Na+ channel 
(ENaC) (Debonneville et al., 2001; Ichimura et al., 2005). SGK isoforms share 
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approximately 55% similarity in the kinase domains with other AGC family kinases 
including Akt and S6K. In vitro SGK recognizes the same phosphorylation consensus 
motif (RXRXXS/T, where X represents any amino acid) as Akt and S6K (McCormick et 
al., 2004). However, unlike Akt and S6K whose expression is relatively stable, SGK1 is 
a short-lived protein whose stability is controlled by the ubiquitin-proteasome pathway 
(Loffing et al., 2006). Both the NEDD4-2 (Brickley et al., 2002; Zhou and Snyder, 2005) 
and CHIP (C-terminal Hsc70-interacting protein) E3 ligases have been shown to 
ubiquitinate SGK1 (Belova et al., 2006). The first 60 amino acids of SGK1 are critical for 
NEDD4-2 mediated destruction of SGK1 (Bogusz et al., 2006; Brickley et al., 2002). In 
addition to growth factor stimulation, cellular stresses including osmotic stress, heat 
shock, oxidative stress and ultraviolet irradiation induce SGK1 expression by 
transcriptional mechanisms and thus influence cell survival, proliferation and 
differentiation (Lang and Cohen, 2001; Loffing et al., 2006). However, it remains unclear 
how SGK1 destruction by NEDD4-2 and CHIP are regulated by these cellular stresses 
and whether other unidentified E3 ligase(s) play a critical role in governing SGK1 
destruction in response to these signaling events. Finally, both Akt and SGK are 
frequently amplified and/or overexpressed in cancers (Sahoo et al., 2005), although the 
underlying molecular mechanisms are unknown. 
 
Here we evaluate the mechanism by which Rictor controls SGK1 stability. We 
found that by specific association with Cullin-1 and Rbx1, Rictor forms a functional E3 
ubiquitin ligase complex that promotes the ubiquitination of SGK1, but not Akt1 or S6K1. 
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We also show that the AGC kinases phosphorylate Rictor at Thr1135 to disrupt the 
Rictor/Cullin-1 complex and impair its E3 ligase activity and subsequent SGK1 
ubiquitination. Our findings demonstrate a kinase-independent function for the Rictor 
protein and provide a mechanistic explanation for the observed elevation of SGK1 
expression in various human tumors. 
(Gao et al., 2010) 
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3. MATERIALS AND METHODS 
 
Cell culture and Cell Synchronization 
Cell culture, including synchronization and transfection, has been described (Gao et al., 
2009).  Lentiviral shRNA virus packaging and subsequent infection of various cell lines 
were performed according to the protocol described previously (Boehm et al., 2005).  
Rictor −/− MEFs and control MEFs were kind gifts from Dr. Mark Magnuson (Shiota et 
al., 2006).  Kinase inhibitors LY294002 (Sigma, L9908), Rapamycin (Calbiochem, 
553210), Wortmannin (Sigma, 95455) and Akt 1/2 Inhibitor VIII (Calbiochem, 124018) 
were used as indicated. 
 
In vitro Kinase Assay 
mTORC2 in vitro kinase assay was performed as described previously (Sarbassov et 
al., 2005). 
 
In vivo Ubiquitination Analysis 
Cells were transfected with a plasmid encoding HA-Δ60-SGK1 along with Flag- or His-
tagged ubiquitin. myc-Rictor or other expression vectors were co-transfected to assess 
their effects on SGK ubiquitination. Thirty-six hours after transfection, 10 μM MG132 
was added to block proteasome degradation, and cells were harvested in EBC buffer or 
denaturing buffer (6 M Guanidine-HCL, 0.1 M NaH2PO4, 10 mM Tris-HCL, 10 mM 
immidazole, pH 8.0) containing protease inhibitor. 2 mg whole cell lysates were 
incubated with Flag beads or Ni-NTA resin for 4–10 hrs, followed by washing 4 times 
with NETN buffer or denaturing washing buffer (8 M urea, 0.1 M NaH2PO4, 10 mM Tris-
	   104	  
HCL, 10 mM immidazole, pH 6.3). Then the washed pellet was boiled in SDS-containing 
lysis buffer and resolved on SDS-PAGE. 
 
In vitro ubiquitination assay 
The in vitro ubiquitination assays were performed as described previously (Jin et al., 
2005).  To purify the Cullin-1/Rictor E3 ligase complex, 293T cells were transfected with 
vectors encoding HA-Cullin-1, Myc-Rictor (WT or T1135E), and Flag-Rbx1. The Cullin-
1/Rictor (E3) complexes were purified from the whole cell lysates using HA-agarose 
beads. Purified, recombinant SGK protein (purchased from Genway) were incubated 
with purified Cullin-1/Rictor (E3) complexes in the presence of purified, recombinant 
active E1, E2 (UbcH5a and UbcH3), ATP and ubiquitin. The reactions were stopped by 
the addition of 2X SDS-PAGE sample buffer and the reaction products were resolved by 
SDS-PAGE gel and probed with the indicated antibodies. 
 
 
Gel Filtration Chromatography for Separation of Rictor Complexes 
Two 10 cm plates of HeLa cells were washed with phosphate buffered saline, lysed in 
0.5 ml of CHAPS lysis buffer (25 mM HEPES pH7.4, 150 mM NaCl, 1 mM EDTA, 0.3% 
CHAPS), and filtered through a 0.45 μm syringe filter. Total protein concentration was 6 
mg/ml. 500 μl of lysate was loaded onto a Superdex 200 10/300 GL column (GE 
Lifesciences Cat. No. 17-5175-01). The experiment in was performed with this same 
column attached in series to a Superose 6 10/300 GL (GE Lifesciences Cat. No.17-
5172-01). The sample was separated in the Superose 6 column first, and then the 
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Superdex 200 column. The gel filtration beads in each column have different size 
exclusion characteristics that complement each other and allow separation of very large 
and also smaller proteins. Chromatography was performed using an AKTAFPLC (GE 
Lifesciences Cat. No. 18-1900-26) and protein complexes were resolved by eluting with 
the same CHAPS buffer at 0.5 ml/min over 3 hours. Eluent was collected in either 250 μl 
or 500 μl fractions. 50 μl aliquots of these fractions were loaded onto SDS-PAGE 
minigels for SDS-PAGE and western blot analysis of the fractionated protein complexes. 
Prior to running cell lysates, the molecular weight resolution of the columns was first 
estimated by running native molecular weight markers (urease ~545 kDa, mouse 
monoclonal IgG ~180 kDa, human serum albumin ~68 kDa) and determining their 
retention times on Coomassie-stained SDS-PAGE protein gels. 
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4.  RESULTS 
 
SGK1 Protein Expression is Regulated by Rictor 
SGK1 is an unstable protein and previous studies have shown that in response to 
serum and growth factors, activation of PI 3-K leads to the induction of SGK1 (Park et 
al., 1999). Induced SGK1 expression occurs partially through the increased 
transcriptional levels of SGK1 mRNA, and partially through other layers of post-
translational regulation (Loffing et al., 2006). However, the exact molecular 
mechanism(s) remain elusive. Recent studies have shown that the Rictor-containing 
mTORC2 complex phosphorylates SGK1 at Ser422 in the hydrophobic motif to fully 
activate SGK1 kinase activity (Garcia-Martinez and Alessi, 2008). We therefore first 
investigated if Rictor signaling can also influence SGK1 expression. We found that 
Rictor−/− MEFs have elevated SGK1 expression levels under serum-deprived 
conditions (Figure 3-1A). In agreement with previous studies (Webster et al., 1993), re-
addition of serum led to a significant induction of SGK1 protein in both wild type and 
Rictor −/− MEFs. Elevated SGK1 expression in Rictor −/− MEFs has been reported 
(Huang et al., 2009), although the underlying molecular mechanism has not been 
characterized. Loss of Rictor is the primary mechanism for the observed elevation of 
SGK1 expression since re-introduction of wild-type Rictor into Rictor−/− MEFs 
dramatically reduced SGK1 expression (Figure 3-1B). Consistent with this, depletion of 
Rictor, but not Raptor, in HeLa cells also led to an accumulation of SGK1 protein, 
primarily in the early G1 phase of the cell cycle (Figure 3-1C). However, Akt1 and S6K1  
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Figure 3-1:  SGK1 expression is regulated by the Rictor pathway 
(A) Whole cell lysates were isolated from wild type or Rictor −/− mouse embryonic 
fibroblasts (MEFs) in serum starvation conditions for 24 hours. In another experimental 
condition, 10% FBS was added to the serum-starved cells for 1.5 hours before 
harvesting. Equal amounts of whole cell lysates were immunoblotted with the indicated 
antibodies. 
(B) Immunoblot analysis of wild type or Rictor−/− MEFs transfected with the Myc-Rictor 
plasmid (with empty vector as a negative control) together with pBabe-Puro retroviral 
empty vector constructs. Twenty-four hours post-transfection, the cells were treated with 
1 μg/ml puromycin for 48–72 hours to kill the non-transfected cells prior to collecting the 
whole cell lysates for immunoblots. 
(C) HeLa cells were infected with the indicated lentiviral shRNA constructs and selected 
with 1μg/ml puromycin to eliminate the non-infected cells. The resulting HeLa cell lines 
were arrested in the M phase by incubation with nocodazole for 18 hours and then 
released into the G1 phase. At the indicated time points, cell lysates were collected for 
immunoblot analysis. 
(D) Quantitative RT-PCR analysis to determine the relative mRNA expression of SGK1 
in wild-type or Rictor-/- cell lines.   
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expression was not affected by depletion of endogenous Rictor in HeLa cells (Figure 3-
1C). Depletion of Rictor does not significantly affect SGK1 mRNA levels (Figure 3-1D), 
indicating that post-translational modification(s) might contribute to the regulation of 
SGK1 by Rictor.  
 
Rictor Promotes SGK1 Ubiquitination in a Cullin-1-dependent Manner 
In support of the finding that Rictor regulates SGK1 stability, we detected an 
interaction between Rictor and SGK1 (Figure 3-2A). We used a cell-based 
ubiquitination assay to address whether Rictor and other mTOR components could 
promote SGK1 ubiquitination. To exclude the possible contribution of other known SGK1 
E3 ligases, including NEDD4-2 and CHIP, we used a deletion mutant of SGK1 that lacks 
the amino-terminal 60 amino acids (Δ60-SGK1), which cannot be efficiently 
ubiquitinated by NEDD4-2 and CHIP (Brickley et al., 2002; Zhou and Snyder, 2005).  
Surprisingly, E3 ligase activity towards SGK1 is unique to Rictor as neither Raptor nor 
mTOR promotes SGK1 ubiquitination (Figure 3-2B). SGK1 was recently identified to be 
a specific downstream substrate of mTORC2 (Rictor), but not mTORC1 (Raptor) 
(Garcia-Martinez and Alessi, 2008). Therefore, we reasoned that SGK1 may specifically 
interact with Rictor, but not Raptor, which could explain why Raptor does not promote 
SGK1 ubiquitination, despite the fact that Raptor was recently shown to exist in a 
complex with Cullin 4 (Ghosh et al., 2008).   
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Figure 3-2: R Rictor promotes SGK1 ubiquitination in  a Cullin-1 dependent 
manner  
 
(A) Immunoblot analysis of whole cell lysates and immunoprecipitates derived from 
293T cells transfected with Flag-Δ60-SGK1 and Myc-Rictor constructs. Thirty hours 
post-transfection, cells were treated with 10 μM MG132 for 10 hours to block the 
proteasome pathway before harvesting. 
(B)Immunoblot analysis of whole cell lysates and anti-HA immunoprecipitates derived 
from 293T cells transfected with the indicated plasmids. Twenty hours post-transfection, 
cells were treated with the proteasome inhibitor MG132 overnight before harvesting. 
(C)Immunoblot analysis of whole cell lysates and immunoprecipitates derived from 293T 
cells transfected with the indicated Myc-Cullin constructs. Thirty hours post-transfection, 
cells were treated with 10 μM MG132 for 10 hours to block the proteasome pathway 
before harvesting. 
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Since Rictor itself does not contain the ring-finger, PHD or HECT domain that 
possesses intrinsic E3 ligase activity, it is possible that Rictor associates with other co-
factor(s) to form an E3 ligase complex. The Cullin-Ring complex comprises the largest 
family of E3 ubiquitin ligases (Petroski and Deshaies, 2005). Thus, we first determined 
which Cullin family member might contribute to SGK1 ubiquitination.  We showed that 
Rictor specifically interacts with Cullin-1, but not other Cullin family members Cullin-2, 3 
and 4 (Figure 3-2C). These data are indicative of a role for Cullin-1 in SGK1 
ubiquitination. 
 
Rictor forms a complex with Cullin-1, Rbx1 to promote SGK1 destruction 
In support of a possible physiological role for both Rictor and Cullin-1 in 
regulating SGK1 stability, we detected the endogenous interaction between Rictor and 
Cullin-1 (Figure 3-3A-B). Furthermore, the endogenous interaction between Rictor and 
Cullin-1 could be detected in NP-40 containing EBC buffer (Figure 3-3B), a condition 
that has been shown to disrupt the mTORC2 complex (Hara et al., 2002; Kim et al., 
2002), indicating that the intact Rictor/mTOR complex might not be required for 
interaction with Cullin-1.  In support of this idea, we showed that Rictor, but not Sin1 or 
mTOR, specifically interacts with endogenous Cullin-1 (Figure 3-3C). Furthermore, 
Cullin-1 only specifically interacts with Rictor, but not Raptor, or other known mTORC2 
components including mTOR, GβL and Sin1, (Figure 3-3D). Although mTOR interacts 
with Rictor more strongly than Cullin-1 in CHAPS buffer, mTOR/Rictor interaction is not 
detected in  
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Figure 3-3: Rictor interacts with Cullin-1 and Rbx1 
(A) Immunoblot  (IB) analysis of 293T whole cell lysates (WCL) and anti-Cullin-1 
immunoprecipitates (IP). Mouse IgG was used as a negative control for the IP.  WCL were 
collected with CHAPS and IPs  were washed with CHAPS buffer.  
(B) IB analysis of 293T WCL and anti-Rictor IP.  Rabbit IgG was used as a negative control for 
the IP procedure.  WCL were collected with EBC  
buffer  and IPs were washed with NETN buffer. 
(C) IB analysis of 293T WCL and anti-Rictor, anti-Sin1, and anti mTOR IP. Rabbit IgG was used 
as a negative control for the IP.  WCL were collected with EBC buffer  and IPs were washed 
with NETN buffer. 
(D) IB analysis of WCL and IP derived from HeLa cells transfected with the HA-Cullin-1 
construct. 
(E) IB analysis of WCL and IP derived from 293T cells transfected with Myc-Rictor together with 
the indicated HA-Rbx1 constructs. Thirty hours post-transfection, cells were pretreated with 10 
μM MG132 for 10 hours to block the proteasome pathway before harvesting.  
(F) IB analysis of WCL and IP derived from 293T cells transfected with HA-Rictor or HA-Fbw7 
constructs together with the indicated Myc-Cullin-1 or Myc-Skp1 constructs. Thirty hours post-
transfection, cells were pretreated with 10 µM MG132 for 10 hours to block the proteasome 
pathway before harvesting. 
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EBC buffer Figure 3-3E) (Hara et al., 2002; Kim et al., 2002). These results suggest 
that Cullin-1 interacts with Rictor in vivo. 
Cullin-1 is an extensively studied member of the Cullin family (Cardozo and 
Pagano, 2004; Harper et al., 2002; Nakayama and Nakayama, 2005). It complexes with 
Rbx1, Skp1 and various F-box proteins to form a multi-protein SCF (Skp1, Cullin-1, F-
box protein) E3 ligase complex (Cardozo and Pagano, 2004; Schulman et al., 2000). To 
further understand the physiological components of the Rictor/Cullin-1 complex, we 
performed gel filtration chromatography. This unpublished data suggests there might be 
two different pools of Rictor complex. One complex was estimated at a size over 600KD 
(fractions 22–26), co-migrating with activated mTOR (as evidenced by S2481 
phosphorylation) and Sin1, which might represent the mTORC2 complex. The other 
Rictor-containing complex was detected at 300–400 KD (fractions 30–34), and co-
migrates with both Cullin-1 and Rbx1, but not Sin1. Since Sin1 is required for mTORC2 
complex formation (Jacinto et al., 2006; Yang et al., 2006), the lack of Sin1 precludes a 
possible existence of the mTORC2 complex in these fractions. In contrast, one Raptor 
complex (mTORC1 complex) is detected, estimated to be over 600KD and co-migrating 
with mTOR. Another detected Raptor peaks at around 180–250KD (fractions 36–40), 
which might represent the free Raptor monomer. Consistent with the co-
immunoprecipitation data (Figure 3-3D), there is no detected co-migration between 
Raptor and Cullin-1 at fractions 29–34 with anticipated size (around 250–400KD) 
corresponding to a possible Raptor/Cullin-1 complex. 
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Using a series of Rbx1 mutants that are unable to interact with Cullin-1, we 
showed that the presence of Cullin-1 is required for Rbx1 and Rictor interaction (Figure 
3-3E). However, we found that under ectopic overexpression conditions Rictor does not 
interact with Skp1 (Figure 3-3F). Altogether, these data support the hypothesis that a 
unique complex composed of Rictor, Cullin-1 and Rbx1 (and possibly other unknown 
partners) is involved in regulating SGK1 abundance. However, it requires further 
investigation to fully understand the role of Skp1 in this process. 
 
Rictor is Phosphorylated by AGC Kinases at T1135 
Although Rictor is a key regulator of both Akt and SGK1, it remains largely 
unknown how its activity is regulated. In agreement with recent reports (Dibble et al., 
2009; Julien et al., 2010; Treins et al., 2010) we found that S6K1 phosphorylates Rictor 
at Thr1135 (Figure 3-4A-B). Furthermore, ectopically expressed Rictor is 
phosphorylated in cells by Akt1 and SGK1 as well (Figure 3-4A-B). Moreover, although 
depletion of S6K leads to a reduction in Thr1135 phosphorylation, depletion of Akt1 or 
SGK1 delivers similar effects and depletion of any individual AGC kinase does not 
significantly affect endogenous Rictor Thr1135 phosphorylation as depletion of mTOR 
does (data not shown). This possibly indicates that all three AGC family kinases might 
function in a redundant manner towards Rictor phosphorylation at Thr1135. A similar 
mechanism has been reported for Foxo3a phosphorylation by AGC kinases (Tran et al., 
2003; Vogt et al., 2005). 
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Figure 3-4: Rictor is phosphorylated at T1135. 
(A)  Immunoblot  (IB) analysis of whole cell lysates (WCL) and immunoprecipitates (IP) 
derived from 293T cells transfected with the indicated Myc-Rictor constructs together 
with various HA-tagged AGC family kinases.   
(B)  Sequence alignment of the putative Rictor T1135 phosphorylation site across 
different species. 
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Phosphorylation of Rictor at T1135 disrupts the Cullin-1/Rictor interaction 
Next we investigated the consequence of Rictor Thr1135 phosphorylation on 
mTORC2 complex activity.  Using gel filtration chromatography, we detected co-
migration of p-Thr1135-Rictor with an active form of mTOR (p-Ser2481) corresponding 
to the mTORC2 complex (fractions 14–20). However, p-Thr1135-Rictor did not co-
migrate with Cullin-1 at 300–400KD (fractions 21–26). Similarly, wild-type-Rictor, but not 
phospho-mimetic Thr1135E-Rictor, co-migrated with Cullin-1 (Figure 3-5A and data not 
shown), indicating that phosphorylation of Rictor at Thr1135 might serve to disrupt the 
Rictor/Cullin-1 complex. 
 
  As shown in Figure 5B, insulin addition into serum starved HeLa cells leads to 
activation of the S6K and Akt kinase pathways (as shown by the increased Ser473-Akt 
and Thr389-S6K signals), which results in increased Rictor phosphorylation at Thr1135, 
coupled with a decrease in Cullin-1/Rictor interaction and enhanced 14-3-3/Rictor 
interaction, and consequently, increased SGK1 abundance.  In a reciprocal set of 
experiments, we treated HA-Cullin-1 expressing cells cultured in 10% FBS-containing 
DMEM medium with LY290042 to inactivate PI 3-K and then monitored how this affects 
the Cullin-1/Rictor interaction. LY treatment induced a time-dependent decrease of 
Rictor Thr1135 phosphorylation, presumably due to the inactivation of S6K and Akt.  
Rictor phosphorylation at Thr135 is inversely correlated with its ability to interact with 
Cullin-1. 
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Figure 3-5: Phosphorylation of Rictor at T1135 disrupts the interaction between 
Rictor and Cullin-1 
 
(A) HeLa cells were transiently transfected with HA-WT-Rictor and Myc-T1135-Rictor 
constructs.  Thirty hours post-transfection, whole cell lysates were collected in CHAPS buffer 
and subjected to gel filtration chromatography. The relative band intensities for HA-WT-Rictor, 
Myc-T1135E-Rictor and p-T1135-Rictor at the indicated fractionations were quantitated.  
(B) HA-Cullin-1 expressing HeLa cells transiently transfected with the Flag-14-3-3 construct.  
Eighteen hours post-transfection, cells were serum-starved for 24 hours.  After the addition of 
100nm Insulin, whole cell lysates (WCL) were collected at the indicated time points for 
immunoblot analysis with the indicated antibodies, for Flag-IP and GST pull-down assays to 
determine Rictor/14-3-3 interaction, and for HA-IP to determine Rictor/Cullin-1 interaction. 
(C) HA-Cullin-1 expressing HeLa cells were treated with 20mM LY294002.  At the indicated time 
points, whole cell lysates (WCL) were collected for immunoblot analysis with the indicated 
antibodies, for HA-IP to determine Rictor/Cullin-1 interaction, and GST-pulldown assays to 
determine Rictor/14-3-3 interaction. 
B 
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Phosphorylation of Rictor at T1135 reduces the ability of Rictor to ubiquitinate 
SGK1 
As a result of reduced interaction with Cullin-1, T1135E Rictor is defective in 
promoting SGK1 ubiquitination (Figure 3-6A).  Since T1135E has similar affinity as wild-
type Rictor in binding to SGK1, the impaired E3 ligase activity towards ubiquitination of 
SGK1 might primarily be due to the disruption of the Cullin-1/Rictor association. 
Moreover, in keeping with impaired E3 ligase activity, compared with wild-type Rictor, 
T1135E Rictor is also compromised in promoting SGK1 degradation (Figure 3-6B).  In 
summary, these data demonstrate that in addition to complexing with mTOR to form the 
mTORC2 complex as a means to phosphorylate Akt and SGK, by complexing with 
Cullin-1 and Rbx1, Rictor might have an additional function as an E3 ligase complex 
that controls the stability of SGK1 and likely additional targets (Figure 3-7). We also 
show that the E3 ligase activity of Rictor is subject to negative regulation by a variety of 
AGC kinases. Since PI 3-K positively regulates AGC kinase activity, frequent 
hyperactivation of this signaling axis might contribute to the elevated SGK1 expression 
levels detected in various cancers (Figure 3-7). 
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Figure 3-6: Phosphorylation of Rictor at T1135 reduces the ability of Rictor to 
ubiquitinate SGK1  
 
(A) Immunoblot  (IB) analysis of whole cell lysates (WCL) and immunoprecipitates (IP) 
derived from 293T cells Transfected with HA-D60-SGK1 together with His-Ub and 
various Myc-Rictor constructs.  Twenty hours post-transfection, cells were treated with 
the proteasome inhibitor MG132 overnight before harvesting.  The whole cell lysates 
were collected in EDTA-free lysis buffer and the His-pull down was carried out in the  
presence of 8M Urea to disrupt possible protein interactions. 
(B) Wild type or Rictor−/− MEFs were transfected with the indicated Rictor plasmids 
(with empty vector as a negative control) together with the pBabe-Puro retroviral empty 
vector. Twenty-four hours post-transfection, the cells were treated with 1 μg/ml 
puromycin for 48–72 hours to kill the non-transfected cells prior to collecting the whole 
cell lysates for immunoblots 
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Figure 3-7: Proposed model for the Rictor/ Cullin-1 pathway to control SGK1 
turnover 
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5.  DISCUSSION 
The data presented above provides experimental evidence for a possible function 
of Rictor in the ubiquitination of SGK1. To date, the only function attributed to Rictor in 
the mTORC2 complex is phosphorylation of the hydrophobic motifs of downstream 
targets such as Akt and SGK. Our data points to a specific association of Rictor with 
Cullin-1 and Rbx1 as part of a possible functional E3 ubiquitin ligase complex (Figure 3-
7). 
Although our results indicate that mTOR may not be required for Rictor E3 ligase 
activity (Figure 3-2B), it remains unclear whether these two complexes share common 
scaffolding proteins and what the crosstalk is between these two complexes. Recent 
studies demonstrate that many other kinase complexes also possess E3 ligase activity 
(Lu et al., 2002; Maddika and Chen, 2009). Since many ubiquitination processes require 
a prior phosphorylation event, the coupling of both the kinase and the E3 ligase in 
proximity provides for more efficient destruction (Carrano et al., 1999). It is possible that 
there are unknown Rictor ubiquitination substrate(s) that require prior phosphorylation 
by Rictor. 
Using gel filtration assays, in addition to the well-known mTORC2 complex 
migrating at over 600KD, we detected a second possible Rictor-containing complex, co-
migrating with Cullin-1 and Rbx1 at 300–400KD. This finding was supported by 
endogenous co-immunoprecipitation assays showing that only Rictor, but not other 
mTORC2 complex components including mTOR, GβL and Sin1 associates with Cullin-1 
(Figure 3-3A-D). We also found that although Sin1 could efficiently immunoprecipitate 
endogenous Rictor, it could not immunoprecipitate endogenous Cullin-1 as Rictor IP 
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does (Figure 3-3D). Since Sin1 is required for formation of the mTORC2 complex 
(Jacinto et al., 2006; Yang et al., 2006), these results suggest that Rictor might exist in 
two distinct complexes, the Sin1-containing mTORC2 complex, and the Cullin-1-
containing complex. This was further supported by the observation that depletion of 
Rictor, Cullin-1 and Rbx1, but not mTOR, Raptor or Sin1 leads to upregulation of SGK1. 
However, additional studies are required to fully understand the possible role of mTOR 
and other TORC2 complex components in Rictor-mediated SGK1 turnover.   
 
Our data also demonstrate that unlike Rictor, Raptor does not promote the 
ubiquitination of Akt1, SGK1 and S6K1 (Figure 3-2B). This suggests that the E3 ligase 
activity might be unique to the Rictor/Cullin-1 complex. However, under ectopic 
expression conditions, Skp1 is not detected in the Rictor/Cullin-1 complex. It is known 
that Skp1 serves as a bridging molecule to hold Cullin-1 and the F-box protein in a 
complex. The possible lack of Skp1 in the Cullin-1/Rictor complex suggests that Rictor 
might play a role equivalent to Skp1. However, further experimental investigation is 
required to fully understand the role of Skp1 for the Rictor/Cullin-1 complex to 
ubiquitinate SGK1, and more studies are also needed to determine whether a specific 
F-box protein is involved in this process. 
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6.  CONCLUSIONS 
Although SGK1 has been shown to be degraded by other E3 ligases including 
NEDD4-2 and CHIP, in both cases it is not known how the destruction is regulated and 
whether it is mediated by PI 3-K signaling. Our data suggest an alternative mechanism 
whereby multiple AGC kinases can negatively regulate Rictor/Cullin-1 E3 ligase activity 
without affecting its kinase activity, and this suggests a positive feedback loop to boost 
SGK1 activity post-stimulation. However, more studies are required to determine 
whether the ability of NEDD4-2 and CHIP to degrade SGK1 is also affected by the PI 3-
K/Akt signaling. SGK1 overexpression has been reported in multiple cancers including 
breast cancer. Most interestingly, although SGK1 has been suggested to have 
redundant functions with Akt, simultaneous overexpression of both Akt and SGK1 has 
also been reported in breast cancers (Sahoo et al., 2005). Our work suggests that since 
SGK1, but not Akt, is subject to ubiquitination by the Rictor/Cullin-1 complex, elevated 
Akt activity might block the function of Rictor/Cullin-1, leading to accumulation of SGK1 
(data not shown). Collectively, our results provide insight into how Rictor can influence 
SGK1 signaling by promoting its ubiquitination. Furthermore, we define a feedback 
mechanism that can negatively regulate the E3 ligase activity of the Rictor/Cullin-1 
complex. This provides functional insight into Rictor regulation, as well as mechanistic 
information regarding the SGK1 stability controlled by the PI 3-K pathway, and how 
misregulation of this process contributes to SGK1 overexpression in human cancers. 
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CHAPTER IV 
DISCUSSION 
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1. SUMMARY OF THESIS 
The objective of my thesis work was to investigate Akt-independent mechanisms of 
PI 3-K signaling in breast cancer.  Gaining a greater understanding of PI 3-K pathways 
that mediate oncogenic PIK3CA signals will help to identify new therapeutic targets and 
better understand the utility of current targets.  In chapter 2, I identify a mechanism of PI 
3-K-dependent SGK3 activation.  I show that the phosphoinositide phosphatase 
INPP4B functions as the regulator between SGK3 and Akt signaling downstream of PI 
3-K.  Moreover, I establish that SGK3 in turn promotes oncogenic phenotypes under 
conditions of low Akt activity and PIK3CA mutation.  I determine that the metastasis 
suppressor, NDRG1, is a critical SGK3 substrate that supports enhanced invasive 
migration in breast cancer cells.  I further demonstrate that NDRG1 phosphorylation by 
SGK3 leads to FBW7 E3 ligase recruitment and subsequent proteolytic degradation.  
The carboxyl-terminal phosphorylation of NDRG1 is the first identified post-translational 
modification that targets its destruction. PI 3-K pathway control of NDRG1 degradation 
is a previously unknown mechanism of PIK3CA-mediated cancer signaling through its 
downregulation of a metastasis suppressor. 
In chapter 3, I explore a novel mTORC2-independent function for Rictor.  I identify 
the Rictor-Cullin1 complex as an SGK1 E3 ligase.  Furthermore, I show that Rictor is 
phosphorylated by AGC family kinases and this inhibits E3 ligase formation, effectively 
serving as a positive signaling feedback loop to SGK1.  The active Rictor-Cullin1 
complex targets SGK1 directing degradation by the proteasome.  Rictor-mediated SGK1 
turnover is the first-identified PI 3-K-dependent post-translational regulation that 
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modulates SGK degradation.  This mechanism highlights a mechanism by SGK1 is 
overexpressed in human cancers as a result of hyperactive PI 3-K signaling.  The UPS 
plays a prominent coordinating role in both aspects of my thesis work, namely SGK1 
regulation by Rictor-Cullin1 and SGK3 regulation by PI 3-K AND INPP4B. The 
implication of these findings in the broader context of PI 3-K signaling in breast cancer 
is discussed below. 
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2.  DISCUSSION 
 
The prevalence of mutations in genes in the PI 3-K pathway across human cancers 
has enabled the development of multiple small molecule inhibitors currently in pre-
clinical and clinical evaluation (Zardavas et al., 2013).  These inhibitors include drugs 
that target PI 3-K itself, or those target its upstream regulators such as RTKs, or its 
downstream effectors such as Akt (Baselga, 2011).  Data emerging from the use of 
these inhibitors in vitro and in genetically engineered mouse models have revealed that 
although we know much concerning the major mechanisms by which PI 3-K relays 
signals to phenotypes associated with malignancy, we do not yet have a complete 
picture (Zardavas et al., 2013).  Since the PI 3-K pathway harbors multiple genes that 
encode both oncogenes and tumors suppressors, and multiple feedback loops exist 
within the signal relay network, it is unlikely that a single linear signaling mechanism 
accounts for the majority of aberrations in cancer.  Moreover, many of proteins that 
transduce PI 3-K signaling exist in multiple isoforms, arguing that one must consider 
redundancy and specificity as a major component of signal relay, that must also be 
taken into account when considering the development of small molecule inhibitors. In 
this context, the best-understood effector of PI 3-K is the Akt kinase and a multitude of 
studies have linked PI 3-K and Akt signaling in the regulation of proliferation, survival, 
metabolic, and motility processes with implications for oncogenic signaling (Luo et al., 
2003). It is not surprising therefore that there are currently a number of small molecule 
Akt inhibitors under clinical evaluation, along with pan PI 3-K and isoform-specific PI 3-K 
inhibitors. Given that some compounds of these have demonstrated limited efficacy 
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either in the laboratory or in the clinic, there is an obvious and unmet need for the 
development of additional inhibitors that target effectors distinct from Akt (Zardavas et 
al., 2013).  This is especially important since studies have revealed that PIK3CA and 
PTEN-mutant tumors do not always display elevated phospho-Akt levels, implying that 
additional effectors may be transducing the PI 3-K and PI(3,4,)P2 and PI(3,4,5)P3 
signals (Vasudevan et al., 2009).  A number of such effectors have received limited 
attention, including novel GEFs for Rho family GTPases, Tec family kinases and SGK 
isoforms (Cherfils and Zeghouf, 2013; Sommer et al., 2013; Vargas et al., 2013; 
Vasudevan et al., 2009). A recent study by the Garraway laboratory demonstrated that 
in certain PIK3CA-mutant cell lines and tumors that do not display high phospho-Akt 
levels and in which Akt is dispensable for growth and proliferation, the SGK3 isoform is 
required for PIK3CA-dependent signaling (Vasudevan et al., 2009). 
Although the Garraway study clearly implicated SGK3 as an effector of PIK3CA in 
cancer, the mechanism by which SGK3 responds to either PI(3,4,)P2 and PI(3,4,5)P3 
has remained elusive. This is especially difficult to rationalize since unlike Akt, SGK3 
does not posses a PH domain capable of binding these two second messengers. 
Instead, SGK3 has a PX domain that binds PI(3)P exclusively, and PI(3)P is generally 
considered to be a phosphoinositide that is constitutively present in endomembranes 
and not function as a classical second messenger (Tessier and Woodgett, 2006b).  
Nonetheless, PI 3-K inhibitor experiments have clearly demonstrated that SGK3 is 
indeed a PI 3-K effector and must therefore respond to elevated PI(3,4,)P2 and 
PI(3,4,5)P3. The mechanism by which SGK3 is activated downstream of PI 3-K has 
	   128	  
remained elusive, in part due to the lack of reagents and tools to study SGK3 
phosphorylation and activation (Tessier and Woodgett, 2006a).  My thesis work has 
focused on identifying such the mechanism by which SGK3 can be activated 
downstream of growth factor-stimulated PI 3-K. Specifically, I show that a critical 
component of this pathway is the INPP4B 4’ lipid phosphatase, that interconverts 
PI(3,4)P2 to PI(3)P. Expression of INPP4B enhances IGF-stimulated SGK3 
phosphorylation, whereas catalytically-inactive INPP4B cannot. Conversely, INPP4B 
silencing with shRNA attenuates SGK3 phosphorylation, protein kinase activity and 
phosphorylation of the downstream substrate NDRG1 as determined in cell-based 
assays.  Since the product of INPP4B activity, PI(3)P, can directly bind to SGK3, I 
propose that INPP4B is rate-limiting in the activation of SGK3 downstream of PIK3CA, 
and thus INPP4B levels ultimately determine whether Akt, or SGK3 is the primary 
effector of this pathway in human tumors. One important aspect is the source of PI(3)P 
in membranes. It is largely accepted that the class III PI 3-K VPS34 that is localized at 
endosomes is responsible for the synthesis of the main pool of PI(3)P in 
endomembranes (Backer, 2008).  However, we show that expression of exogenous 
VPS34 does not enhance SGK3 activity. Moreover, VPS34 deletion in fl/fl MEFs also 
has no effect on the IGF-stimulated SGK3 phosphorylation. Therefore, the pool of 
PI(3)P generated by VPS34 is unlikely to be directly involved in SGK3 activation. 
Instead, I propose that it is the PI(3)P that is interconverted from PI(3,4)P2 by INPP4B 
in cells that have elevated levels of this phosphatase combined with PI 3-K pathway 
mutations that lead to increased PI(3,4,)P2 and PI(3,4,5)P3.  As such, this model 
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dictates that SGK3 is a positive transducer of INPP4B activity.  The model that elevated 
INPP4B can positively regulate signaling, rather than simply being viewed as a tumor 
suppressor whose loss promotes Akt activation, also implies that other PX domain-
containing proteins that sense PI(3)P could be regulated by this alternate pathway. 
Furthermore, the concept that INPP4B can promote PI 3-K signaling by its presence, 
and not just by its loss, characterizes new potential combination therapies in the 
PIK3CA pathway. Combination therapies targeting PI 3-K and SGK3 may hold promise 
for those tumors that harbor PIK3CA mutation, SGK3 amplification and constitutive or 
elevated INPP4B. Luminal ER positive tumors are likely to represent one such 
molecular subtype, since these tumor have the highest frequency of PIK3CA mutations, 
do not frequently lose INPP4B by LOH, and SGK3 is often over-expressed and/or 
amplified.  
In Chapter 2, I show that SGK3 is focally amplified in breast cancer with an overall 
amplification rate of 54%.  I then show that SGK3 and INPP4B regulate oncogenic 
phenotypes such as growth in 3D and invasive migration in cells that harbor oncogenic 
PIK3CA but display low-level Akt phosphorylation/activation.  The relative number of 
tumors and tumor cell lines that exhibit minimal Akt activity and in which Akt is 
dispensable for proliferation emphasizes the importance of understanding alternate 
mechanisms of PI 3-K-driven cancer progression. The ability of SGK3 to mediate 
tumorigenic phenotypes is likely due in part to its overlapping substrates with Akt.  The 
number of substrates shared between Akt and SGK3 emphasizes the ability of SGK3 to 
regulate oncogenic phenotypes via shared signaling pathways.  However, identifying 
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specific mechanisms by which activated SGK3 might regulate cancer phenotypes that 
are not shared with Akt holds promise for new drug targets and biomarkers for clinical 
benefit. In my studies I identify an exclusive SGK substrate, NDRG1, as a mediator of PI 
3-K signaling in the SGK3 pathway. Moreover, my data reveal the mechanism by which 
a post-translational modification leads to NDRG1 destruction by the proteasome. These 
data also highlight a novel mechanism by which PI 3-K/SGK3 regulates degradation of a 
breast cancer metastasis suppressor (Figure 4-1). In this model oncogenic PIK3CA 
promotes invasive migration in breast cancer through the INPP4B/SGK3 signaling axis. 
The ability of SGK3 to promote progression adds to our knowledge of the mechanisms 
of PI 3-K signal relay, and further indicate that SGK3 is an effector that can transduce 
signals in the absence of productive Akt activation.  
Initial studies showed that INPP4B is primarily expressed in luminal A and luminal B 
molecular subtypes in breast cancer.  The expression of INPP4B in ER positive 
cancers, and its loss by LOH in ER negative breast cancers implies that lipid 
phosphatase activity may not exclusively function in a signal termination capacity in the 
context of PI 3-K signaling, at least in ER positive cancers.  Instead, I propose that in 
ER positive breast cancers, INPP4B catalytic activity diverts the signal towards PI(3)P 
and recruitment and activation of SGK3.  This event in turn promotes downstream 
SGK3 signaling, while inhibiting PIK3CA-stimulated Akt activation, since PI(3,4,)P2 is 
eliminated.   In this model, those rate-limiting factors that determine activation of Akt 
versus SGK3, are INPP4B protein levels and SGK3 amplification.  Although other 
factors likely determine the ability of PIK3CA to drive SGK3 activation, I propose that the  
	   131	  
 
 
 
Figure 4-1: Model of PI 3-K regulation of Metastasis Suppressor NDRG1 through 
SGK3 
 
SGK3 activation via the PI 3-K is mediated by INPP4B catalytic activity likely through its 
conversion of PI(3,4)P2 to produce PI(3)P which recruits and binds the SGK3 PX 
domain. 
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primary determinant is INPP4B expression. It is also worth noting that this is not 
necessarily an all-or-nothing mechanism. It is likely that in certain breast cancers both 
Akt and SGK3 are activated simultaneously, possibly under conditions where the levels 
of INPP4B allow for some de novo PI(3)P synthesis but the pool of PI(3,4,)P2 is also 
retained. The mutual induction of SGK3 and INPP4B in ER+ cells differentiates ER+ 
from ER- PI 3-K signaling.  
The fact that INPP4B functions as a positive mediator of PI 3-K signaling in ER 
positive tumors, and not solely as a signal terminator changes the way we view INPP4B 
as a therapeutic target.  In triple negative breast cancers, INPP4B has been shown to 
function as a tumor suppressor, such that INPP4B LOH is commonly observed 
(Gewinner et al., 2009).  A tumor with this profile will likely respond very differently to 
Akt inhibitors compared to an ER positive tumor with high INPP4B and high SGK3.  My 
studies highlight the emerging concept of personalized medicine and the evaluation of 
the specific genetic background of a tumor to be able to administer the appropriate drug 
treatment.  As such, I propose that INPP4B can function both as an oncogene and 
tumor suppressive, depending on the genetic background, although this concept has not 
yet been tested in vivo.  However, the notion that genes can function as both oncogenes 
and tumor suppressors depending on the context is not new. For example, studies in 
Notch signaling and Mouse Double Mutant 2 (MDM2) have helped to establish the 
concept of dual modalities of a single gene (Manfredi, 2010; South et al., 2012). Thus, 
the notion that a gene and its protein product have a unique function in all tumor 
settings is an over-simplification, and this must be taken into account when devising 
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treatment strategies.  Although the model that INPP4B can function as an oncogene or 
tumor suppressor, and that SGK3 can mediate the oncogenic function, it is likely that 
there exist additional INPP4B effectors that are yet to be described, and that likely 
contribute to oncogenic function.  
In Chapter 3 we identify a new E3 ubiquitin ligase complex composed of Rictor and 
Cullin1, which directs the degradation of SGK1 at the proteasome.  The Rictor-Cullin1 
E3 complex is the first example of an mTORC2-independent function for Rictor. 
Interestingly, the mTORC1 subunit, Raptor, was previously shown to have mTOR-
independent E3 ligase functions in complex with Cullin4 (Ghosh et al., 2008).  Duality in 
the abilities of kinase complexes to intersect and perform E3 ligase functions leading to 
degradation increases the probability of coordination in cellular events.  This raises the 
probability that the two Rictor- containing complexes crosstalk or signal feedback to one 
another.  The turnover rate for each complex is also likely to have diverse effects on the 
processing rate of the competing complex.   
Rictor is phosphorylated at Thr1135 by members of the AGC family of kinases 
including Akt and S6K, and this event functions to negatively regulate the Rictor-Cullin 
complex.  PI 3-K-mediated Thr1135 regulation modulates the levels of SGK1 and this 
mechanism increases our understanding of SGK regulation at the post-translational 
level. The participation of Akt in promoting SGK1 expression adds to its known role in 
the phosphorylation of WNK1, where by WNK1 functions as a scaffolding protein for 
PDK-1-mediated phosphorylation of SGK1 at Thr256.  The dual mechanisms of Akt in 
the regulation of SGK1 activity and expression underscore the importance of signal 
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integration necessary for efficient pathway output.  The Rictor-Cullin1 complex is the 
first SGK E3 ligase identified that functions in a PI 3-K-dependent manner. A logical 
extension of this finding is that oncogenic PIK3CA and PTEN mutations perturb SGK1 
degradation.  Under conditions of deregulated PI 3-K activity, SGK1 protein levels 
increase leading to hyperactivation of SGK1 downstream targets.    
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3. FUTURE DIRECTIONS 
 
My work has identified a novel mechanism by which PI 3-K transduces lipid signals 
to SGK3, specifically through the activity of the lipid phosphatase INPP4B. In addition, I 
have identified a mechanism of regulation of the SGK substrate NDRG1. A number of 
open questions remain regarding the details by which SGK3 responds to PI 3-K 
signaling. One obvious question is the mechanism of localization that determines 
activation SGK3, given that previous studies have localized SGK3 primarily at the 
endosome, consistent with the notion that endosomal membranes contain the bulk of 
the intracellular PI(3)P pool . However, my model dictates that the activity of INPP4B on 
PI(3,4)P2 thereby generating PI(3)P drives SGK3 activation. Since PI(3,4)P2 and 
PI(3,4,5)P3 are largely generated at the plasma membrane, this implies that the 
resulting PI(3)P must also accumulate at the plasma membrane, thus allowing for SGK3 
recruitment through the PX domain leading to activation. By inference, INPP4B is 
unlikely to be responsible for PI(3)P production at the endosomal membrane, consistent 
with published findings demonstrating that endosomal localization of SGK3 is PIK3CA-
independent (Tessier and Woodgett, 2006a). In this model, the two distinct pools of 
PI(3)P exist, one endosomal generated by VPS34 that primarily functions in vesicle 
trafficking, and a second INPP4B-generated pool at the plasma membrane that is 
responsible for mediating PIK3CA signals. In both cases, SGK3 senses PI(3)P, but may 
ultimately dictates specific functions. At the same time, we cannot exclude the possibility 
that the two pools are interchangeable, or that the plasma membrane pool of PI(3)P and 
SGK3 integrates with the endosomal pools. Regardless, obtaining formal proof for a 
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plasma membrane localization of PI(3)P and SGK3 has proven challenging. We 
attempted to make use of Total Internal Reflection Fluorescence (TIRF) microscopy to 
specifically detect SGK3 plasma membrane recruitment.  Unfortunately, the 
overexpression of Green Fluorescent Protein (GFP)-tagged SGK3 generated 
considerable background fluorescence that precluded a consistent and robust 
evaluation of SGK3 membrane recruitment.  An alternate method to investigate distinct 
SGK3 pools would be the use of self-quenching SNAP-tags to label SGK3 and examine 
SGK3 localization with fluorescent confocal and TIRF microscopy.  SNAP-tags should 
theoretically have the advantage of reduced background allowing for increased 
resolution.  Alternatively, the development of more specific and high affinity antibodies 
for phospho-SGK3 at pThr320 and pSer486 for use in IHC applications would be an 
important development.  Such antibodies would allow for the examination of localization 
of endogenous SGK3 especially in cells and tissues with known PI 3-K genetic lesions.  
Further insight would be gained by examining the phosphoprotein profile IGF-1 
stimulation or PIK3CA mutation in cells in which INPP4B has been silenced. Membrane 
interactions could be isolated after such treatments followed by mass spectrometry 
analysis to determine candidates of positively and negatively regulated INPP4B targets.  
This information would expand our understanding and add perspective to SGK3 
signaling and may aid in the targeting of ER-positive breast cancers with combination 
therapy.  
. 
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 Another important step forward will be to generate genetically engineered mouse 
models that recapitulate finding that SGK3 can function as a PIK3CA and INPP4B 
effector. This would be especially interesting in the setting of ER-positive tumors, and 
examination of subsequent tumor growth and metastasis.  One would predict that 
INPP4B silencing would mimic the phenotypes seen by SGK3 silencing.  Although 
SGK3 isoform knockout mice have been made, they have only informed the contribution 
of SGK in embryonic development.  Studies in adult mice in the context of tumor 
phenotypes have not been performed. Moreover, there is no combined 
SGK1/SGK2/SGK3 knockout mouse to address possible SGK familial signaling roles. 
Another gap in understanding is the nature of SGK3-specific substrates, or at least 
SGK-specific substrates that are not shared with Akt, other than NDRG1. Identifying 
such substrates will likely provide an important advance in our understanding of the 
mechanisms by which SGKs mediate cancer phenotypes. Finally, if specific total and 
phospho-specific SGK3 antibodies that are of sufficient quality for IF can be developed, 
one obvious application will also be to use confocal microscopy in the context of growth 
of tumor cells in 3D culture to determine changes in SGK1 and SGK3 localization, 
phosphorylation and activity to provide insight into spatial-temporal regulation of SGK.  
 The data pointing to NDRG1 as a metastasis suppressor through its modulation 
of Wnt signaling and E-cadherin recycling highlights a potential for a therapeutic 
strategy.  However, a more detailed analysis of the NDRG1 phospho-degron remains an 
important issue, since NDRG1 does not possess a canonical FBW7 degron sequence. 
However, it does share similarities in the SGK3 and GSK3β decapeptide repeat to 
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typical degrons.  The priming of the phospho-degron by GSK3β and the tandem 
phosphorylated serine and threonine sites are common characteristics of FBW7 sites.  
A logical extension of the studies presented in this thesis would be to mutate the 
NDRG1 carboxyl-terminal sites to alanine, and evaluate binding to FBW7 (Figure 4-2). 
Additionally, mass spectrometry analysis of the phosphorylation sites should be carried 
out under conditions of stimulation and in combination with a panel of protein kinase 
inhibitors (SGK, GSK3β, PI 3-K). 
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Figure 4-2:  Phospho-site analysis for NDRG1 
Mapping of known phosphorylation sites for NDRG1 produced from mass spectrometry 
evaluation.  Adapted from phosphosite.org. 
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 The studies outlined in Chapter 3 provide evidence for an mTORC2- independent 
function for Rictor.  One logical extension of these studies is to determine if scaffolding 
proteins common to Rictor in both the E3 ligase complex and mTORC2 exist.  The 
absence of Skp1 in the Rictor-Cullin1 complex suggests that there may be alternate 
scaffolding proteins bridging Cullin1 to its F-box protein.  The possibility remains that 
Rictor alone could mediate a bridging function or there could be additional components 
of the Rictor-Cullin1 complex that are essential to assemble a functional complex.  
Understanding which precise subunits within the E3 ligase complex directly interact will 
increase our understanding of complex formation.  This knowledge will also guide the 
development of drugs that interrupt SGK1 degradation as a viable therapeutic option.  
Another important consideration is the consequence of the Rictor Thr1135 
phosphorylation.  There are two main models: Thr1135 phosphorylation could simply 
prevent the de novo assembly of Rictor-Cullin1, or alternatively Thr1135 
phosphorylation could lead to spatial inhibition of the binding of complex components, 
and ultimate disassembly. The phosphorylation of Thr1135 generates a positive 
feedback loop that promotes the accumulation of SGK1.  The deregulation of this 
feedback in cells with oncogenic PI 3-K pathway mutations may be causal with respect 
to SGK1 overexpression in human cancer.  In this context, published studies have 
established a significant correlation between SGK1 overexpression and high levels of 
pAkt1 S473 in breast tumor samples (Sahoo et al., 2005). Additional examination of 
tumor samples with high SGK1 levels for enhanced Thr1135 Rictor phosphorylation will 
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help to establish the amplitude of the feedback loop. This same feedback loop 
negatively regulates Rictor, adding to our understanding of Rictor regulation and 
downstream signaling consequences.  The existence of two Rictor complexes begs 
questions of stoichiometry between the pools.  Although technically challenging, it will 
be interesting to examine the ability of one mTORC2 complex to sequester Rictor at the 
expense of the activity of the other. Our studies also establish the need to determine the 
extent of Rictor-Cullin1 as an E3 ligase and if its role in the UPS extends to other 
proteins or is exclusive to SGK1.  It would be interesting to investigate the ability of 
Rictor to function as both a priming kinase within the phospho-degron and then to 
sequentially function as an E3 ligase for poly-ubiquitination. The synchronization of 
priming and poly-ubiquitination would challenge the participation of DUBs and provide 
insight into the mechanistic organization of cellular processes. 	  	   The synergy of Akt isoforms and SGK isoforms as effectors of PIK3CA and other 
PI 3-K pathway lesions likely leads to alterations in expression and activation of SGK1 
and SGK3 under distinct phases of tumor development.  Examining expression patterns 
of SGK1 in 3D spheroid growth and changes in expression resulting from altered Akt or 
SGK3 activity would help to explore the dynamic relationship between SGK isoforms 
and other AGC family kinase members.  Moreover, since no specific SGK isoform-
specific inhibitors have been developed, I propose our work provides the impetus for the 
development of such drugs, as they may provide an unmet need for tumors with specific 
pathway alterations.  
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4. FINAL NOTE 
 
In summary, the data described in this thesis identifies two Akt-independent PI 3-K 
mediators, SGK1 and SGK3, that are hyperactivated in human cancers.  The 
contribution of SGK3 amplification to PIK3CA signaling in breast cancers provides 
insight for a potentially novel therapeutic target.  This thesis identifies INPP4B as a 
switch that determines pathway output to Akt or SGK3 in the PI 3-K pathway.  I propose 
that INPP4B functions as both as an oncogene in luminal type breast cancer in the 
context of PIK3CA mutations, in addition to its well-documented role as a tumor 
suppressor in basal like/triple negative breast cancers. This concept reinforces the 
notion that complete understanding of the genetic context of a given tumor must be 
considered so that ultimately, the appropriate treatment regimen is prescribed. 
Furthermore, the work described in this thesis reveals a new pathway by which PI 3-K 
regulates the degradation of a metastasis suppressor, NDRG1, through SGK3.  This 
finding also argues that there exists specificity between SGK and Akt signaling, rather 
that redundancy between the two kinase pathways. The identification of an mTORC2- 
independent function for Rictor proposes a more coordinated view of protein 
degradation. AGC kinase negative feedback regulation of Rictor ligase activity 
synergizing with Thr1135 phosphorylation highlights a mechanism by which PI 3-K 
activity promotes the overexpression of SGK1 and likely enhancement of PI3KCA 
signaling.  The chapters of this thesis are related in that they focus on poly-
ubiquitination and proteasomal degradation as a central feature to control signaling 
events.  The deregulation of ubiquitination during oncogene-driven cancer progression 
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is also a central theme in this thesis.  Most obvious is the concept that SGK isoforms 
contribute to breast cancer cell phenotypes in the context of PI 3-K signaling.  These 
findings provide a more comprehensive understanding of PI 3-K biology and the 
emerging concept of importance of Akt-independent signaling.  Finally, from a 
therapeutic perspective, the data outlined in this thesis advocate the development and 
implementation of combination therapies using small molecule inhibitors targeting SGK 
and Akt isoforms for maximal efficacy. 	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